Title of Invention

"3-CYANO-QUINOLINE COMPOUNDS AS KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND PROCESS FOR PREPARATION"

Abstract The present invention relates to 3-Cyano-qinoline compounds as kinase inhibitors of formula: wherein Z, Y, X1, X2 R1 to R3 are as described in the specification. The present invention also relates to a pharmaceutical composition comprising the same and a process for preparing the said compound.
Full Text The present invention relates to 3-cyano-quinoline compounds as kinase inhibitors, pharmaceutical composition thereof and process for preparation.
This invention relates to quinoline derived macrocycles that have been found to possess anti-proliferative activity, such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body, for example in the manufacture of medicaments for use in hyper proliferative disorders such as atherosclerosis, restenosis and cancer. The invention also relates to processes for the manufacture of said quinoline derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of anti-proliferative effect.
In particular, the compounds of the present invention were found to inhibit tyrosine kinase enzymes, also called tyrosine kinases. Tyrosine kinases are a class of enzymes, which catalyse the transfer of the terrninal phosphate of adenosine triphosphate to the phenolic hydroxyl group of a tyrosine residue present in the target protein. It is known, that several oncogenes, involved in the transformation of a cell into a malignant tumour cell, encode tyrosine kinase enzymes including certain growth factor receptors such as EGF, FGF, IGF-1R, IR, PDGF and VEGF This family of receptor tyrosine kinases and in particular the EGF family of receptor tyrosine kinases, hereinafter also referred to as EGFR receptor or EGF type receptor tyrosine kinases, are frequently present in common human cancers such as breast cancer, non-small cell lung cancers including adenocarcinomas and squamous cell cancer of the lung, bladder cancer, oesophageal cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, cancer of the prostate, leukaemia and ovarian, bronchial or pancreatic cancer, which are examples of cell proliferation related disorders.
Accordingly, it has been recognised that the selective inhibition of tyrosine kinases will be of value in the treatment of cell proliferation related disorders. Support for this view is provided by the development of Herceptin® (Trastuzumab) and Gleevec™ (imatinib mesylate) the first examples of target based cancer drugs. Herceptin® (Trastuzumab) is targeted against Her2/neu, a receptor tyrosine kinase found to be amplified up to 100-fold in about 30% of patients with invasive breast cancer. In clinical trials Herceptin® (Trastuzumab) proved to have anti-tumour activity against breast cancer (Review by L.K. Shawer et al, "Smart Drugs: Tyrosine kinase inhibitors in cancer therapy", 2002, Cancer Cell Vol.1, 117), and accordingly provided the proof of principle for therapy targeted to receptor tyrosine kinases. The second example, Gleevec™ (imatinib mesylate), is targeted against the abelson tyrosine kinase (BcR-Abl), a constitutively active cytoplasmic tyrosine kinase present in virtually all patients with chronic myelogenous leukaemia (CML) and 15% to 30% of adult patients with acute lymphoblastic leukaemia. In clinical trials Gleevec™ (imatinib mesylate) showed a spectacular efficacy with minimal side effects that led to an approval within 3 months of submission. The speed of passage of this agent through clinical trials and regulatory review has become a case study in rapid drug development (Drucker B. J. & Lydon N., "Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia.", 2000, J.Clin.Invest. 105, 3).
Further support is given by the demonstration that EOF receptor tyrosine kinase inhibitors, specifically attenuates the growth in athymic nude mice of transplanted carcinomas such as human mammary carcinoma or human squamous cell carcinoma (Review by T.R. Burke Jr., Drugs of the Future, 1992, 17,119). As a consequence, there has been considerable interest in the development of drugs to treat different cancers that target the EGFR receptor. For example, several antibodies that bind to the extra-cellular domain of EGFR are undergoing clinical trials, including Erbitux™ (also called C225, Cetuximab), which was developed by Imclone Systems and is in Phase HE clinical trials for the treatment of several cancers. Also, several promising orally active drugs that are potent and relatively specific inhibitors of the EGFR tyrosine kinase are now well advanced in clinical trials. The AstraZeneca compound ZD1839, which is now called IRESSA® and approved for the treatment of advanced non-small-cell lung cancer, and the OSI/Genentech/Roche compound OSI-774, which is now called Tarceva™ (erlotinib), have shown marked efficacy against several cancers in human clinical trials (Morin M.J., "From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents, 2000, Oncogene 19, 6574).
In addition to the above, EGF receptor tyrosine kinases has been shown to be implicated in non-malignant proliferative disorders such as psoriasis (elder et al., Science, 1989,243; 811). It is therefore expected that inhibitors of EGF type receptor tyrosine kinases will be useful in the treatment of non-malignant diseases of excessive cellular proliferation such as psoriasis, benign prostatic hypertrophy, atherosclerosis and restenosis.
It is disclosed in US patents US 6,288,082 and US 6,002008, in the International Patent Applications WO 98/43960 and WO 00/018761 and in J. Med. Chem, 2000,43(17), 3244 that certain 4-aniUno-3-cyanoquinolines may be useful as inhibitors of tyrosine kinase and in particular of the EGF type receptor tyrosine kinases. Unexpectedly it was
found that 3-cyanoquinoline derivatives of the present formula (T) that are different in structure show to have tyrosine kinase inhibitory activity.
It is accordingly an object of the present invention to provide further tyrosine Idnase inhibitors useful in the manufacture of medicaments in the treatment of cell proliferative related disorders.
This invention concerns compounds of formula (I)
(Figure Removed)
the JV-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
Z represents O, NH or S;
Y represents -C3-9alkyl-, -C3-9alkenyl-, -C1-5alkylalkyl-oxy-C1-5alkylalkyl-,
-Ci-5alkyl-NR12-Ci.3al]qrl-5-C1-5alkyl-NR13-CO-C1-5alkyl-,
-C1-5alkyl-CO-NR14-C1-5a]kyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-,
-CO-NH-d-ealkyl-, -NH-CO-C1-6alkyl-, -CO-C1-7alkyl-, -C1-7alkyl-CO-,
Cwalkyl-CO-C1-6alkyl,-C1-2alkyl-NH-CO-CH2R15-NHs X1 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO- C1-2alkyl-, NR10,
-NE.10-C1-2alkyl-, NR16-CO-, NR16-CO-C1-2alkyl, -O-N=CH- or d.2alkyl; X2 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO- C1-2alkyl-, NR11,
NRn-C1-2alkyl-,NR17-CO-,NR17-CO-C1-2alkyl, Het20-C1-2alkyl5 -O-N=CH- or d.
2alkyl;
R1 represents hydrogen, cyano, halo, hydroxy, formyl, C1-6alkoxy-, C1-6alkyl-, C1-6alkoxy- substituted with halo,
Chalky! substituted with one or where possible two or more substituents selected from hydroxy or halo;
R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het16-carbonyl-, C1-4alkyloxycarbonyl-, C1-4alkylcarbonyl-, aminocarbonyl-, mono-or di(C1-4aJkyl)aminocarbonyl-, Het1, alkyl, C1-4alkyl-, C2-6alkynyl-, C2-6cycloalkyl-, C3-6cycloalkyloxy-, C1-6alkoxy-, Ar5, A1oxy-, dihydroxyborane , C1-6alkoxy- substituted with halo, C1-6alkyl substituted with one or where possible two or more substituents selected
from halo, hydroxy or NR4R5,
C1-6alkylcarbonyl- wherein said C1-4alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C1-4alkyl-oxy~; R3 represents hydrogen, hydroxy, Ar3-oxy, Ar4-C1-6alkyloxy-, C1-6alkyloxy-,
Caalkenyloxy- optionally substituted with Het12 or R3 represents C1-6alkyloxy substituted with one or where possible two or more substituents selected from C1-6alkyloxy-, hydroxy, halo, Het2-, -NRV, -carbonyl- NR8R9 or Het3-carbonyl-; R4 and R5 are each independently selected from hydrogen or C1-6alkyl; R6 and R7 are each independently selected from hydrogen, C1-6alkyl, Het8,
aminosulfonyl-, mono- or di (C1-6alkylJ-amhiosulfonyl, hydroxy-C1-6alkyl-, C1-6alkyl-oxy-C1-4alkyl-, hydroxycarbonyl-C1-6alkyl-, C3-6cycloalkyl, Het9-carbonyl-C1-4alkyl-, Het10-carbonyl-, polyhydroxy-C1-4alkyl-, Hetn-C1-4alkyl- or
R8 andR9 are each independently selected from hydrogen, C1-4alkyl,
Het4, hydroxy-Cwalkyl-, C1-4alkyloxyC1-4alkyl- orpolyhydroxy-C1-6alkyl-;
R10 represents hydrogen, C1-4alkyll, Het5, Het6-C1-4alkylalkyl-, C2-4alkenylcarbonyl-
optionally substituted wilh Het7-C1-4alkylaminocarbonyl-, C2-4alkenylsulfonyl-, C1-4alkyloxyC1-6alkyl- orphenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-6alkyloxy-;
R11 represents hydrogen, C1-4alkyl, C1-4alkyl-oxy-carbonyl-, Het17, Het18-C1-4alkyl-, Caalkenylcarbonyl- optionally substituted with Het19-C1-4alkylaminocarbonyl-, Caalkenylsulfonyl-, C1-6alkyloxyC1-6alkyl- orphenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-6alkyloxy-;
R12 represents hydrogen, Calkyl, Het13, Het14-C1-4alkyl- orphenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-4alkyloxy-;
R13 andR14 are each independently selected from hydrogen, C1-4alkyl, Het15-C1-6alkyl-or
R15 represents hydrogen or C1-4alkyl! optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl, aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; R16 andR17 are each independently selected from hydrogen, C1-6alkyl, Het21-C1-4alkyl
or C1-4alkyloxyC1-4alkyl;
Het1 represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het1 is optionally substituted amino, C1-6alkyl, hydroxy-CMaliyl-, phenyl, phenyl-C1-6alkyl-, C1-6alkyl-oxy-C1-6alkyl- mono- or di(C1-6alkyl)amino- oramino-carbonyl-; Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het1 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C1-4 alkyl-, hydroxy-C1-4alkyl-, C1-6alkyl-oxy-C1-6alkyl-, hydroxy-C1-6alkyl-oxy-C1-6alkyl-, mono- or di(C1-6alkyl)amino-, mono- or diCCwalliytyarnmo-C1-6alkyl-, aminoC1-4alkyl-, mono- or di(C1-4alkylalkyl)amhio-sulfonyl-, aminosulfonyl-; Het3, Het4 and Het8 each independently represent a heterocycle selected from
morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het3, Het4 or Het8 is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C1-4alkyl-, C3-6cycloalkyl-C1-6alkyl-, aminosulfonyl-, mono- or di(C1-4alkyl)aminosulfonyl or amino-C1-6alkyl-;
Het5 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkylor polyhydroxy-Cwalkyl-;
Het6 and Het7 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3-6cycloalkyl, hydroxy-C1-6alkyl-, C1-4alkyloxyC1-6alkyl or polyhydroxy-C1-6alkyl-;
Het9 and Het10 each independently represent a heterocycle selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het9 or

Het0 is optionally substituted C1-4alkyl!,C3-6cycloalkylcycloalkyl-C1-4alkyl- or
(Figure Removed)
Het11 represents a heterocycle selected from indolyl or Het12 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het12 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C1-6alkyl-, hydroxy-C1-6alkyl-, C1-4alkyl-oxy-C1-6alkyl-, hydroxy-C1-4altyl-oxy-C1-6alkyl-, mono- or di(C1-4alkyl)amino- or mono- or di(C1-6alkyl)amino-C1-4alkyl-j
Het13 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl,C3-6cycloalkylcycloalkyl, hydroxy-C1-4allkyl-, C1-6alkyloxyCialkyl or polyhydroxy-C1-4alkyl-;
Het14 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more sabstituents selected from C1-4alkyl!,C3-6cycloalkylcycloalkyl, hydroxy-Ciallkyl-, C1-4alkylalkyloxyC1-6alkyl or polyhydroxy-C1-6alkyl-; Het15 and Het21 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycles are optionally substituted with one or where possible two or more substituents selected from C\. 4alkyl, Cs-gcycloalkyl, hydroxy-C1-6alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C1-4alkyl!; and Het17 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from duality!, Ca-gcycloalkyl, hydroxy-C1-4alkyl-,
Het18 and Het19 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycles are optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3_6cycloalkyl, hydroxy-C1-6alkyl-, C1-6alkyloxyC1-4alkyl or polyhydroxy-C1-6alkyl-;
Het20 represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolyl or pyrazolidinyl wherein said heterocycle is
optionally substituted with one or where possible two or more substituents selected from C1-4alkyL, C3-6ycloalkyl, hydroxy-C1-4alkyl-, C1-6alkyloxyC1-6alkyl or polyhydroxy-C1-4alkyl-; in particular Het20 represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl, piperidinyl, piperazinyl or pyrazolidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3-6ycloalkyl, hydroxy-C1-6alkyl-, C1-6alkyloxyC1-6alkyl orpolyhydroxy-C1-4alkyl-; and
Ar1, Ar2, Ar3, Ar4 and Ar5 each independently represent phenyl optionally substituted with cyano, C1-6alkylsulfonyl-, C1-6alkylsulfonylamino-, aminosulfonylamino-, hydroxy-C1-6alkyl, aminosulfonyl-, hydroxy-, C1-6alkyloxy-
As used in the foregoing definitions and hereinafter,
- halo is generic to fluoro, chloro, bromo and iodo;
- C1-4alkyl defines methyl or ethyl;
- C1-4alkyl defines straight and branched chain saturated hydrocarbon radicals having
from 1 to 3 carbon atoms such as, for example, methyl, ethyl, propyl and the like;
- C1-4alkyl defines straight and branched chain saturated hydrocarbon radicals having
from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like;
- C1-4alkyl! defines straight and branched chain saturated hydrocarbon radicals having
from 1 to 5 carbon atoms such as, for example, methyl, ethyl, propyl, buiyl, pentyl, 1-methylbutyl, 2,2-dimethylpropyl, 2,2-dimethylethyl and the like;
- Cjalkyl is meant to include C1-5alkyi and the higher homologues thereof having 6
carbon atoms such as, for example hexyl, 1,2-dimethylbutyl, 2-methylpentyl and the like;
- C1-7alkyl is meant to include C1-6alkyl and the higher homologues thereof having 7
carbon atoms such as, for example 1,2,3-dimethylburyl, 1, 2-methylpentyl and the like;
- C3-9alkyl defines straight and branched chain saturated hydrocarbon radicals having
from 3 to 9 carbon atoms such as propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and
the like;
- C2.4alkenyl defines straight and branched chain hydrocarbon radicals containing one
double bond and having from 2 to 4 carbon atoms such as, for example vinyl, 2-
propenyl, 3-butenyl, 2-butenyl and the like;
- Ca-palkenyl defines straight and branched chain hydrocarbon radicals containing one
double bond and having from 3 to 9 carbon atoms such as, for example 2-propenyl, 3-
butenyl, 2-butenyl, 2-pentenyl, 3-penteuyl, 3-methyl-2-butenyl, 3-hexenyl and the like;
defines straight and branched chain hydrocarbon radicals containing one triple bond and having from 2 to 6 carbon atoms such as, for example, 2-propynyl, 3-butynyl, 2-butynyl, 2-pentynyL, 3-pentynyl, 3-methyl-2-butynyl, 3-hexynyl and the like;
- Cacycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;
- C1-4alkyloxy defines straight or branched saturated hydrocarbon radicals such as
methoxy, ethoxy, propyloxy, butyloxy, 1-methylethyloxy, 2-methylpropyloxy and the
like;
- Ci-ealkyloxy is meant to include Qalkyloxy and the higher homologues such as
methoxy, ethoxy, propyloxy, butyloxy, 1 -methylethyloxy, 2-methylpropyloxy and the
like;
- polyhydroxy-C1-6alkyl is generic to a C1-6alkyl as defined hereinbefore, having two,
three or were possible more hydroxy substituents, such as for example trifluoromethyl.
As used in the foregoing definitions and hereinafter, the term formyl refers to a radical of formula -€H(=O).
The heterocycles as mentioned in the above definitions and hereinafter, are meant to include all possible isomeric forms thereof, for instance pyrrolyl also includes 1H-pyrrolyl; triazolyl includes 1,2,4-triazolyl and 1,3,4-triazolyl; oxadiazolyl includes 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl; thiadiazolyl includes 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl and 1,3,4-thiadiazolyl; pyranyl includes 2£T-pyranyl and 4fiT-pyranyl.
Further, the heterocycles as mentioned in the above definitions and hereinafter may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heterocycle is imidazolyl, it may be a 1-imidazolyl, 2-imidazolyl, 3-imidazolyl, 4-imidazolyl and 5-imidazolyl; when it is thiazolyl, it may be 2-tbiazolyl, 4-thiazolyl and 5-thiazolyl; when it is triazolyl, it may be 1,2,4-triazol-l-yl, l,2,4-triazol-3-yl, l,2,4-triazol-5-yl, 1,3,4-triazol-1-yl and l,3,4-triazol-2-yl; when it is benzothiazolyl, it may be 2-benzothiazolyl, 4-benzothiazolyl, 5-benzotbiazolyl, 6-benzothiazolyl and 7-benzo1hiazolyl.
The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic
acid; sulruric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyravic, oxalic, malonic, succinic (i.e. butane-dioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, emanesulfoniCjbeiizenesulfomCjp-toluenesulfonic, cyclamic, salicylic, jj-aminosalicylic, pamoic and the like acids.
The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I) are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, JV-methyl-D-gmcamine, hydrabamine, amino acids, e.g. arginine, lysine.
Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.
The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.
The term stereochemically isomeric forms as used hereinbefore defines the possible different isomeric as well as conformational forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
Some of the compounds of formula 00 may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
The AT-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called JV-oxide.
A preferred group of compounds consists of those compounds of formula (I) wherein
one or more of the following restrictions apply :
Z represents NH;
Y represents -C3.9alkyl-, -C2-9alkenyl-, -Ci-5alkyl-oxy-C1-5alkyl-,
-C1-5alkyl-NR12-Ci-5alkyl-, -Ci-ealkyl-NH-CO-, -CO-C1-4alkyl-, -d-yaliyl-CO- or
X1 represents O, -O-C1-2alkyl-, -O-N=CH-, NR10 or -NR10-C1-2alkyl-; in a particular
embodiment X1 represents -O- or -O-CHa-;
X2 represents a direct bond, O, -O-C1-2aLkyl-, -O-N=CH-, C1-2alkyl, NR11 or NRn-C1-2alkyl-; in a particular embodiment X2 represents a direct bond, -0-N=CH-, -NRn-C1-2alkyl-, -NRCHa-, -C1-2alkyl-, -O-C1-2alkyI, -O-or-O-CHz-;
R1 represents hydrogen, cyano, halo or hydroxy, preferably halo; R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Ci_
4alkyloxycarbonyl-, Het16-carbonyl-, C1-4alkynyl-, Ar5 or Het1;
In a farther embodiment R2 represents hydrogen, cyano, halo, hydroxy,
Caaliynyl-orHet1; R3 represents hydrogen, hydroxy, Cwalkyloxy-, Ar4-C1-6alkyloxy or R3 represents
Cualkyloxy substituted with one or where possible two or more substituents
selected from C1-6alkyloxy- or Het2-; R10 represents hydrogen, C1-6alkyl- or C1-4alkyl-oxy-carbonyl-; R11 represents hydrogen, C1-6alkyl- or Cijalkyl-oxy-carbonyl-; R12 represents Het14-C1-6alkyl, in particular morpholinyl-C1-4alkyl; Het1 represents thiazolyl optionally substituted amino, C1-6alkyl, hydroxy-C1-6alkyl-,
phenyl, phenyl-Cwalkyl-, C1-6alkyl-oxy-C1-4alkyl- mono- or di(C1-4alkyl)amino-
or amino-carbonyl-; Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or Cialkyl-;
In a further embodiment Het2 represents a heterocycle selected from morpholinyl
or piperidinyl optionally substituted with C1-6alkyl-, preferably methyl; Het14 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het14 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C1-6alkyl-; Het16 represents a heterocycle selected from piperidinyl, morpholinyl or pyrrolidinyl; Ar4 represents phenyl optionally substituted with cyano, hydroxy-, C1-4alkyloxy or
Ar5 represents phenyl optionally substituted with cyano, hydroxy, Ci-ialkyloxy or
A further group of compounds consists of those compounds of formula (I) wherein one
or more of the following restrictions apply :
Z represents NH;
Y represents -C3-9allcyl-, -C1-5a]kyl-NR12-Ci-5alkyl-, -C1-6alkyl-NH-CO- or
-CO-NH -Ci-ealkyl- ; X1 represents -O-; X2 represents a direct bond, -NRn-C1-2alkyl-, -NRn-CH2-, -C1-2alkyl-, -O-C1-4aSkyl,
-O-or-O-CH2-; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkylalkyloxycarbonyl-,
Het16-carbonyl- or Ar5; R3 represents hydrogen, hydroxy, C1-6alkyloxy-, Ar4-Ciuialkyloxy or R3 represents
Ciallcyloxy substituted with one or where possible two or more substituents
selected from C1-6alkyloxy- or Het2-; R10 represents hydrogen;
R11 represents hydrogen, C1-4alkyl!- or C1-6alkyl-oxy-carbonyl-; R12 represents Het14-C1-4alkyl, in particular morpholinyl-Ciallcyl; Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C1-6alkyl-;
In a further embodiment Het2 represents a heterocycle selected from morpholinyl
or piperidinyl optionally substituted with C1-6alkyl-, preferably methyl; Het14 represents morpholinyl;
Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar4 represents phenyl; Ar5 represents phenyl optionally substituted with cyano.
Another group of compounds consists of those compounds of formula (I) wherein one
or more of the following restrictions apply:
Z represents NH;
Y represents -C3_9alkyl-, -Cs-palkenyl-, -C1-5alkyl-oxy-C1-5alkylalkyl-,
-C1-5alkylalkyl-NR-C1-5alkylalkyl-, -C1-5allcyl-NR13-CO-C1-5allcyl-, -C1-4alkyl-NH-CO-,
-CO-C1-4alkyl-, -Ci.7alkyl-CO- or Cwalkyl-CX)-C1-6alkyl;
X1 represents O, -O-C1-2alkyl-, -O-N=CH-, NR16-CO, -NR16-CO-C1-2aIkyl-, NR10 or
-NR10-C1-2alkyl-; in a particular embodiment X1 represents -O-, -O-CEfe-j NR10 or
-NR10-C1-2alkyl-; X2 represents a direct bond, O, -O-C1-2aliyl-, -O-N=CH-, Het-Ci-aalkyl, C1-2alkyl,
NR17-CO, -NR17-CO-C1-2aliyl-, NR11 or NRn-C1-2alkyl-; in a particular
embodiment X2 represents a direct bond, -O-N=CH-, -NRCi-aalkyl-,
-NRn-CH2-, Het-C1-6alkyl, NR17-CO, -NR17-CO-C1-2alkyl- -C1-2alkyl-,
-O-C1-2alkyl, -O- or -O-CH2-;
R1 represents hydrogen, cyano, halo or hydroxy, preferably halo; R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Ci-
4alkyloxycarbonyl-, Het16-carbonyl-, C2alkynyl-, Ar5 or Het1;
In a furiber embodiment R2 represents hydrogen, cyano, halo, hydroxy,
C1-4alkynyl-orHet1; R3 represents hydrogen, hydroxy, Cwalkyloxy-, Ar4-C1-4alkyloxy or R3 represents
Cj-4alkyloxy substituted with one or where possible two or more substituents
selected from C1-4alkyloxy- or Het2-; R10 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R11 represents hydrogen, C1-4alkyl- or C1-6alkyl-oxy-carbonyl-; R12 represents Het14-C1-4alkyl, in particular morpholinyl-C1-6alkyl; R16 represents hydrogen, C1-6alkyl-, Het-C1-6alkyl or C1-4alkylaliyl-oxy-C1-6alkyl; hi
particular R16 represents hydrogen or C1-4alkyl;
R17 represents hydrogen, C1-4alkyl-, HetCiutalkyl or Ci-jalkyl-oxy-C1-6alkyl; in particular R16 represents hydrogen or C1-6alkyl;
Het1 represents thiazolyl optionally substituted amino, Ci-«alkyl, hydroxy-C1-6alkyl-, phenyl, phenyl-C1-6alkyl-, C1-4allcyl-oxy-C1-4alkyl- mono- or di(C1-6alkyl)amino-or amino-carbonyl-;
Het2 represents a heterocycle selected fiom morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C1-4alkyl!-; In a turther embodiment Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-4alkyl!-, preferably methyl;
Het14 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het14 is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C1-6alkyl-;
Het16 represents a heterocycle selected from piperidinyl, morpholinyl or pyrrolidinyl;
Het20 represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl or piperidinyl;
Het21 represents a heterocycle selected from morpholinyl, piperazuayl, piperidinyl or pyrrolidinyl wherein said Het21 is optionally substituted wifh one or where possible two or more substituents selected from hydroxy, amino or C1-6alkyl-;
Ar4 represents phenyl optionally substituted with cyano, hydroxy-, C1-6alkyloxy or Cualkyl;
Ar5 represents phenyl optionally substituted with cyano, hydroxy, C1-6alkyloxy or C1-4alkyl.
A farther group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: Z represents NH;
Y represents -C3-9aUtyl-, -C1-5alkyl-NR12-C1-5alkyl-, -Cial-NR -C1-4alkyl-CO-NR14-Ci.3alkyl-, -d-ealkyl-NH-CO- or -CO-NH -in particular Y represents -Ca-salkyl-, -C1-5alkyl-NR12-C1-5alkyl-, -C1-5alkyl-NR13-CO-C1-5alkyl-, -C1-6alkyl-NH-CO- or-CO-NH-C1-4alkyl-; X1 represents a direct bond, NR10, -NR10-C1-2alkyl->, -NR10-C3I2-5 -C1-2alkyl-,
-OCiallcyl, -O- or-O-GH2-;
X2 represents a-O-, MR11, NR17-CO, NR17-CO-C1-2alkyl or Het-C1-6alkyl; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycacbonyl-, C1-4alkyloxycarbonyl-,
Hetld-carbonyl-orAr5j
R3 represents hydrogen, hydroxy, C1-4alkyloxy-, Ar4-C1-4alkyloxy or R3 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-; R10 represents hydrogen;
R11 represents hydrogen, CuaUcy!- or C1-4aHcyl-oxy-carbony!-; R12 represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkylalkyl; R13 represents hydrogen; R17 represents hydrogen;
Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible two or more substitaents selected from hydroxy, amino or Cwalkyl-; In a further embodiment Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-6alkyl-, preferably methyl; Het14 represents morpholinyl;
Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Het20 represents pyrrolidinyl or piperidinyl;
Ar4 represents phenyl;
Ars represents phenyl optionally substituted with cyano.
Other special group of compounds are:
- those compounds of formula (I) wherein -X1- represents -O-;
- those compounds of formula (T) wherein -X1- represents -NR10-, in particular -NH-;
- those compounds of formula (I) wherein -X2- represents -NR17-CO-C1-2alkyl-, in
particular -NH-CQ-C1-4allsyl-;
- those compounds of formula (T) wherein -X2- represents represents -NR11 -C1-4aHcyl,
in particular ~NH-C1-2alkyl-;
- those compounds of formula (I) wherein -Y- represents
-C1-5alkyl-mI3-CO-Ci-5alkyl- or -C1-5alkyl-CO-lSIR14 -C1-4alkyl!-, in particular
-C1-5alkyl-NH-CO-C1-5alkyl-;
- those compounds of formula CO wherein R1 is fluoro, chloro or bromo;
- those compounds of formula (I) wherein R2 is fluoro, chloro or bromo;
- those compounds of formula (I) wherein R1 and R2 represent halo, in particular those
1 O
compounds of formula (I) wherein R represents fluoro and R represents chloro;
- those compounds of formula (I) wherein R2 is Het1, in particular thiazolyl optionally
substituted with methyl;
those compounds of formula (I) wherein R2 is C2-6alkynyl-, in particular ethylyn;
- those compounds of formula (I) wherein R2 is Ar5, in particular phenyl optionally
substituted with cyano;
- those compounds of formula (I) wherein R3 represents methoxy and wherein said
methoxy is at position 7 of the structure of formula (I).
- those compounds of formula (I) wherein R3 represents C1-6alkyloxy substituted with
one substituent selected from C1-6alkyloxy- or Het2-, in particular propyloxy
substituted with momholinyl;
- those compounds of formula (I) wherein R11 is hydrogen or C1-4alkyl-, in particular
methyl or wherein R11 is C1-6alkyl-oxy-carbonyl-, in particular t-butyl-oxy-carbonyl-
- those compounds of formula (I) wherein Het2 represent morpholinyl optionally
substituted with Cualkyl, preferably morpholinyl attached through the nitrogen
atom to the remainder of the compounds of formula (I);
- those compounds of formula (I) with Het3 represent morpholinyl optionally
substituted with C1-4alkyl, preferably morpholinyl attached through the nitrogen
atom to the remainder of the compounds of formula (I);
- those compounds of formula (I) wherein Het12 represent morpholinyl optionally substituted with C1-6alkyl, preferably morpholinyl attached through the nitrogen atom to the remainder of the compounds of formula (I).
In a further embodiment of the present invention the R1 substituent is at position 4', the
jy *3
R substituent is at position 5' and the R substituent at position 7 of the structure of formula (I).
The compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry and described for instance in the following references; "Heterocyclic Compounds"- Vol.24 (part4) p 261-304 Fused pyrimidines, Wiley - Interscience; Chem. Pharm. Bull., Vol 41(2) 362-368 (1993); J.Chem.Soc.5 Perkin Trans. 1,2001,130-137.
(Figure Removed)
YI and Y2 represent a Cj.5alkyl or C0-C1-5alkyl
X3 and X4 represent optionally protected iunctional groups, such as for example a primair, secundair or tertiair amine, hydroxy or halo (Cl, Br or I), which upon reaction produce together with the Yt respectively Y2 substituent to which they are attached, the divalent Y radical as defined for formula (I)
As further exemplified in the experimental part of the description, the compounds of formula (I) wherein X1 represents -O- were generally prepared starting from 6-acetoxy-4-chloro-3-cyanoquinoHnes of formula (EL), which can be prepared from the known 5-acetoxy-4-alkoxy-2-nitrobenzoic acid (Scheme 2).
Coupling of this quinoline of formula (IT) with suitable substituted anilines (IS), which in their turn can be prepared according to reaction schemes 3-7, furnish the intermediate compounds (TV).
Deprotection of the intermediates of formula (TV) as described in Protective Groups in Organic Synthesis by T.W. Greene and ROM Wilts, 3rd edition, 1998 followed by ring
closure under Mitsunobu conditions give the target compounds (I) (Scheme 1).
R
(Figure Removed)
V = protective group such as for example methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl
groups
R18 represents Ar3, Ar4-C1-4alkyl, C1-4alkyl, C1-4alkenyl optionally substituted with Het12 or R18
represents C1-4aHcyl substituted with one or where possible two or more substituents selected from
C1-4alkyloxy, hydroxy, halo, Het2, NR6R7, NR8R9-carbonyl or Het3-carbonyl, wherein Ar3, Ar4, Het12,
Het2, R6, R7, R8, R9and Het3 are defined as for the compounds of formula (T)
The 6-acetoxy-4-cUoro-3-cyano-quinoline (IT) may be produced according to scheme 2. In this synthesis scheme the 2-amino-benzoic ester derivative (VET) may be produced by esterifying the 5-acetoxy-4-methoxy-2-nitrobenzoic acid (V), for example with dimethylsul&ric acid in the presence of a base, for example potassium carbonate and then reducing the nitro group for example with iron/acetic acid Next the compound (VH) thus obtained is converted into the quinoline ring of formula (EX) according to a method described, for example with 1,1-dimemoxytrimethylamine (DMFDMA) in dimethylformamide (DMF), followed by an electrophilic substitution reaction to introduce the 3»cyano substituent
Next the 3-cyano-quinoline derivative thus obtained is chlorinated by action of a chlorinating agent for example SOCla in DMF to yield the quinoline derivative of formula (H).
(Figure Removed)
R18 represents Ar3, Ar4-C1-4alkyl, C1-4alkyl, C2alkenyl optionally substituted with Het12 or R18 represents C1-4alkyl substituted with one or where possible two or more substituents selected from Cjalkyloxy, hydroxy, halo, Het2, NR6R7, NR-carbonyl or Het3-carbonyl, wherein Ar3, Ar4, Het12, Het2, R6, R7, R8, R9and Het3 are defined as for the compounds of formula (T)
For those compounds where X2 represents -O-, the suitable substituted anilines of formula (HI") are generally prepared from the commercially available nitro-phenols (X) and the a, co-protected halogenated alcohols (XI) under alkaline conditions in a reaction inert solvent, for example, using dimethylacetamide (DMA) in the presence of KjCOs. The resulting nitro-phenyl derivative (XII) is subsequently reduced according to standard conditions, for example, using iron/acetic acid, to yield the substituted anilines of formula (IIP) (Scheme 3).
(Figure Removed)
JL-VU. those compounds where X2 represents -NRxl-or -NRn-C1-2alkyi-, the suitable substituted anilines of formula (HI1*) are generally prepared from the commercially available 2-nitro-benzaldehydes (XIII) and the amine substituted alcohols (XIV) by reductive amination under standard conditions, for example using NaBILt and titanium(iv)isopropoxide as reducing agents in ethanol as solvent, yielding in a first step the rdtro-benzylamines of formula (XV).
Next the primary ftee alcohol is protected using art known procedures, for example, using an esterification reaction with acetic anhydride in the presence of pyridine. The thus obtained intermediate of formula (XVT) is subsequently reduced according to standard conditions, for example, using iron/acetic acid to yield the substituted anilines of formula (HI15) (Scheme 4).

(Figure Removed)
V represents a protective group such as for example methylcarbonyl
For those compounds where X2 represents ~O-N=CH-, the suitable substituted anilines of formula (HI6) are generally prepared according to reaction scheme 5. In a first step the known 2-nitro-benzaldehydes (XIII) are converted into the corresponding oxime (XVII) using, for example, the art known condensation reaction with hydroxylamine.
Next said oxime of formula XVH is allowed to react with an halogenated alkylacetate under alkaline conditions, for example using KaCOa in DMSO, followed by reducing the nitro group, for example, with iron/ acetic acid, to provide the suitable substituted aniline of formula (HI0).

(Figure Removed)
For those compounds where X2 represents a direct bond and Y represents C1-6alkyl-NH-CO-, the suitable substituted anilines of formula (HI15) are generally prepared according to reaction scheme 6.
In a first step the known 2-nitro-benzoic acids (XX) are amidated to the intermediates of formula (XXH) under art known conditions, for example, using a hydroxylated amine of formula (XXI) that is added dropwise to a mixture of (XX) in CHbCb in the presence of 1,1 'carbonylbis-lH-imidazole.
Next the primary tree alcohol is protected using art known procedures, for example, using an esterification reaction with acetic anhydride in the presence of pyridine. The thus obtained intermediate of formula (XXpI) is subsequently reduced according to standard conditions, for example, using iron/acetic acid to yield the substituted anilines of formula (md).
(Figure Removed)
For those compounds where X2 represents a direct bond the suitable substituted anilines of formula (El6) are generally prepared according to reaction scheme 7. In a first step the known 2-nitro-benzaldehydes (Xin) are alkenated to the intermediates of formula (XXV) under art known conditions, for example, using the Wittig Reaction with the appropriate phosphonium salt of formula (XXTV). Following esterification of the tree carboxylic acid under standard conditions for example, using ethanol under acidic conditions, the intermediate of formula (XXVT) are reduced to yield the desired substituted anilines of formula (HI6).
(Figure Removed)
Alternatively, those compounds of formula (I'1*) wherein Y represents
-C1-2alkyl-NH-CX)-CH2R15-NH- or -Ci-5alkyl-CO-NR14-C1-5alkyl-are prepared using the following synthesis scheme. The intermediates of formula (TV*) are obtained as described hereinbefore. Deprotection and subsequent formation of the corresponding ether using the appropriate aminated alcohol under standard conditions provides the intermediates of formula (XXVUI). Deprotection followed by ring closure provides the target compounds of formula (Isb).
(Figure Removed)
V ~ protective group such as for example, methylcarbonyl, t-utyl, methyl, ethyl, beuzyloxycaibonyl or trialkylsilyl groups, or in case of solid phase chemistry the resin to which the remainder of the molecule is attached
R18 represents Ar3, Ar4-Cjalkyl, C1-4alkyl, C2alfcenyl optionally substituted with Het12 or R18 represents C1-4alkyl substituted with one or where possible two or more substituents selected from CMa]iyloxy, hydrojqf, halo, Het2, NR*R7, NR-carbonyl orHel?-carbonyl, wherein Ar3, Ar4, Het12, Het2, Rs, R7, R8, R9 and Het3 are defined as for the compounds of formula (0 Yj and Y2 each independently represent a C1-4alkyl, CO-C j_5alkyl or CO-CH2R1S-NH-
Where necessary or desired, any one or more of the following further steps in any order
may be performed:
(i) removing any remaining protecting group(s);
(ii) converting a compound of formula (I) or a protected form thereof into a further
compound of formula (I) or a protected form thereof; (iii) converting a compound of formula (I) or a protected form thereof into aN-oxide, a
salt, a quaternary amine or a solvate of a compound of formula (I) or a protected
form thereof; (iv) converting a -TV-oxide, a salt, a quaternary amine or a solvate of a compound of
formula (I) or a protected form thereof into a compound of formula (I) or a protected
form thereof;
(v) converting a Moxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another AT-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula (T) or a protected form thereof;
(vi) where the compound of formula (I) is obtained as a mixture of (R) and (S) enantiomers resolving the mixture to obtain the desired enantiomer.
Compounds of formula (I), JV-oxides, addition salts, quaternary amines and stereochemical isomeric forms thereof can be converted into further compounds according to the invention using procedures known in the art
It will be appreciated by those skilled in the art that in the processes described above Hie functional groups of intermediate compounds may need to be blocked by protecting groups.
Functional groups, which it is desirable to protect, include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, lert-butyldiphenylsilyl or trimethyisilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butyloxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C1-4alkyl or benzyl esters.
The protection and deprotection of functional groups may take place before or after a reaction step.
Additionally, the N-atoms in compounds of formula (T) can be methylated by art-known methods using CHs-I in a suitable solvent such as, for example 2-propanone, tetrahydrofuran or dimethylformamide.
The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation of which some examples are mentioned hereinafter.
The compounds of formula (I) may also be converted to the corresponding JV-oxide forms following art-known procedures for converting a trivalent nitrogen into its JV-oxide form. Said j-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an
appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g. counter-current distribution, liquid chromatography and the like.
Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enanliomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, cbiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or • compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, hi particular liquid chromatography using a chiral stationary phase.
Some of the intermediates and starting materials as used in the reaction procedures mentioned hereinabove are known compounds and may be commercially available or
may be prepared according to art-known procedures. However, in the synthesis of macrocyclic kinase inhibitors, such as for example the compounds of formula (I), the present invention further provides; a) the intermediates of formula (ID)
(HI) the pharmaceutically acceptable addition salts and the stereochemically isomeric forms
thereof, wherein
Y represents -C1-4alkyl-, -C3-9alkenyl-, -C1-5alkyl-oxy-C1-5alkyl-, -C1-5alkyl-NR12-C1-5alkyl-,-C1-5alkyl-NR13-CO-C1-5alkyl-, -C1-4alkyl-CO-NR14-C1-5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO~, -Ci.7alkyl-CO-, C1-6alkyl-CO-C1-6alkyl; X2 represents a direct bond, O, -O-C1-2aIkyl-, CO, -CO- C1-2alkyl-s MR11,
-NRn-Ci.2alkyl-, ~CH2-, -O-N=CH- or d.2alkyl;
R1 represents hydrogen, cyano, halo, hydroxy, formyl, C1-6alkoxy-, C1-6alkyl-, dalkoxy- substituted with halo, C1-6alkyl substituted with one or where possible two or more substituents selected
from hydroxy or halo; and
R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het1 from halo, hydroxy or NR4R5,
C1-4 alkylcarbonyl- wherein said C1-4alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C1-4alkyl-oxy-;
R4 and R5 are each independently selected from hydrogen or C1-6alkyl; R11 represents hydrogen, C1-6alkyl, C1-6alkyl-oxy-carbonyl-, Het17, Het18-C1-4alkyl-, C2-4alkenylcarbonyl- optionally substituted with Het19-C1-4alkylaminocarbonyl-, C2-4alkenylsulfonyl-, C1-6alkyloxyC1-4ialkyl- orphenyl optionally substituted with one or where possible two or more substituents selected from hydrogen., hydroxy, amino or C1-4alkyloxy-;
R12 represents hydrogen, C1-4alkyl, Het13, Hetw-C1-4alkyl- orphenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-6alkyloxy-; R13 and R14 are each independently selected from hydrogen, C1-6alkyl, Het15-C1-6alkyl-
or C1-4alkyloxyC1-6alkyl-;
Het1 represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherehi said Het1 is optionally substituted amino, C1-4alkyl, hydroxy-C1-4alkyl-, phenyl, phenyl-C1-4alkyl-, CiJjalkyl-oxy-C1-4alkylalkyI- mono- or di(C1-4alkyl)amino- or amino-carbonyl-; Het13 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3-6ycloalkyl, hydroxy-Ciallkyl-, CiJjalkyloxyC1-6alkyl or polyhydroxy-C1-4alkyl-;
Het14 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het14 is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, C3-6cycloalkyl, hydroxy-C1-6alkyl-, C1-6alkyloxyC1-6alkyl or polyhydroxy-C1-6alkyl-; Het15 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het15 is optionally substituted with one or where possible two or more substituents selected from CiaDcyl,C3-6cycloalkylcycloalkyl, hydroxy-C1-4alkyl-, C1-6alkyloxyC1-6alkyl or polyhydroxy-Cjalkyl-; Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl Wherein said heterocycle is optionally substituted with one or more substituents selected from C1-4alkyl!; and Het17 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6ycloalkyl, hydroxy-C1-4alkyl-, CialiyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het18 and Het19 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherehi said Het18 and Het19 are optionally substituted with one or where possible two or more substituents selected from C1-4alkyl!, C3-6ycloalkyl, hydroxy-Cualkyl-, C1-6alkyloxyC1-6alkyl or polyhydroxy-C1-6alkyl-;
Ar1, Ar2, Ar3, Ar4 and Ar5 each independently represent phenyl optionally substituted with cyano, C1-6alkylsulfonyl-, CwaD£ylsulfonylamino-, aminosiilfonylainino-, hydroxy-C1-6alkyl, aminosulfonyl-, hydroxy-, C1-6alkyloxy- or
In particular the intermediates of formula (III) wherein one or more of the following
restrictions apply; i) Y represents -C3-9alkyl-, -Ci-5alkyl-oxy-C1-5alkyl-, -C1-5alkyl-NR12-C1-5alkyl-,
ii) X2 represents a direct bond, O, -O-Ci.jalkyl-, NR11, -NRC1-6alkyl-, -CH2-,
-O-N=CH-orC1-2alkyl;
iii) R1 represents hydrogen, cyano, halo or hydroxy, preferably halo; iv) R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
C1-6alkyloxycarbonyl-, Het16-carbonyl-, C1-6alkyl-, C1-4alkynyl-, Ar5 or Het1;
In a further embodiment R2 represents hydrogen, cyano, halo, hydroxy,
Caalkynyl- or Het1; in particular R2 represents hydrogen, cyano, halo, hydroxy, or
Ar5;
v) R11 represents hydrogen, C1-4alkyl, or C1-6alkyloxycarbonyl; vi) R12 represents Het14-C1-4alkyl, in particular morpholinyl-C1-6alkyl; vii) Het1 represents thiazolyl optionally substituted with ammo, Qalkyl,
hydroxy-C1-6alkyl-, phenyl, phenyl-C1-6alkyl-, Cialiyl-oxy-C1-6alkyl- mono- or
di(C1-4alkyl)amino- or amino-carbonyl-; ii) Het16 represents a heterocycle selected from piperidinyl or pyrrolidinyl.
b) the intermediates of formula (XXX)
(Figure Removed)
the pharmaceutically acceptable addition salts and the stereochemically isomeric forms
thereof, wherein
Yi and Y2 each independently represent C1-4alkyl!, CO-C1-5alkyl or X1 represents a direct bond, O, -O-Ci.2aIkyl-, CO, -CO- Ci.2alkyl-, NR10,
-NR-dalkyl-, -CH2-, -O-N=€H- or -C1-2alkyl-; X2 represents a direct bond, O, -O-Ci.2aIkyl-, CO, -CO- C1-2alkyl-, MR11,
-C1-6alkyl-, -CH2-, -O-N=CH- orCi.2alkyl; R1 represents hydrogen, cyano, halo, hydroxy, formyl, C1-6alkoxy-,
- substituted with halo,
C1-4alkyl! substituted with one or where possible two or more substituents selected
from hydroxy or halo; and
R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het16-carbonyl-, C1-6alkyloxycarbonyl-, Ctalkylcarbonyl-, aminocarbonyl-, mono-or di(C1-4alkyl)ammocarbonyl-, Het1, formyl, dalkyl-, C2-6alkynyl-,
l-, Cscycloalkyloxy-, C1-4alkoxy-, Ai5, Aroxy-, dihydroxyborane ,
- substituted with halo,
substituted with one or where possible two or more substituents selected from halo, hydroxy or NR5,
C1-6alkylcarbonyl- wherein said CiaUey! is optionally substituted with one or where possible two or more substituents selected from hydroxy or
R4 andR5 are each independently selected from hydrogen or C1-4alkyl!;
R6 andR7 are each independently selected from hydrogen, C1-4alkyl!, Het8,
arninosulfonyl-, mono- or di (C1-6alkyl)-aminosulfonyl, hydroxy-C1-6alkyl-, CMalJkyl-oxy-C1-6alkyl-, hydroxycarbonyl-C1-6alkyl-,C3-6cycloalkylcycloalkyl, Het9-carbonyl-C1-4alkyl-, Het10-carbonyl-, polyhydroxy-CMaJkyl-, Hetn-C1-4alkyl-
R8 andR9 are each independently selected from hydrogen, C1-4aJkyl, Cscycloalkyl, Het4, hydroxy-C1-6alkyl-, C1-6alkyloxyC1-4alkyl- orpolyhydroxy-C1-4alkylalkyl-;
R10 represents hydrogen, C1-4alkyl, CMaHcyl-oxy-carbonyl-, Het17, Het18-C1-4alkyl-, C2-4alkenylcafbonyl- optionally substituted with Het19-C1-6alkylaminocarbonyl-,C3-6cycloalkylallcenylsulfonyl-, C1-6alkyloxyC1-6alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-6alkyloxy-;
Ra represents hydrogen, C1-4alkyl, Het13, Het14-C1-6alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-4alkyloxy-;
R18 represents Ar3, Ar4-C1-6alkyl, C1-4alkyl], C2-«alkenyl optionally substituted with Het12 or R18 represents C1-4alkyl! substituted with one or where possible two or more substituents selected from C1-6alkyloxy, hydroxy, halo, Het2, NR6R7, NR8R9-carbonyl or Het3-carbonyl;
R15 represents hydrogen or dalkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl, aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino;
Het1 represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het1 is optionally substituted amino, C1-4alkyl], hydroxy-C1-6alkyl-, phenyl, phenyl-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl- mono- or di(C1-6alkyl)amino- or amino-carbonyl-;
Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherehi said Het2 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C1-4alkyl!-, hydroxy-C1-6alkyl-, C1-4alkyl-oxy-C1-4alkyl-, hydroxy-C1-6alkyl-oxy-C1-4alkyl-, mono- or di(C1-4alkyl)amino-, mono- or di(C1-4alkyl)amino-C1-4alkyl-, aminoCi-ialkyl-, mono- ordi(C1-6alkyl)ammo-sdibnyl-, aminosulfonyl-;
Het3, Het4 and Het8 each independently represent a heterocycle selected from
morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het3, Het4 or Het8 is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C1-6alkyl-,
l-, aminosulfonyl-, mono- or di(C1-6alkyl)aminosulfonyl or
and Het10 each independently represent a heterocycle selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Her9 or Het10 is optionally substituted C1-4alkyl!, C3- (Figure Removed)
Het11 represents a heterocycle selected from indolyl or
Het12 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het12 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, Cwalkyl-, hydroxy-C1-4alkyl-, dalkyl-oxy-C1-6alkyl-, hydroxy-Ciutalkyl-oxy-C1-6alkyl-, mono- or di(C1-6alkyl)amino- or mono- or dXCiallsyl)amino-C1-4alkyls
Het13 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said Het13 is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl!,C3-6cycloalkylcycloalkyl, hydroxy-Ciallkyl-, CwalkyloxyC1-4allcyl or polyhydroxy-C1-6alkyl-;
Het14 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, Cscycloalkyl, hydroxy-Ciallkyl-, Ci-alkyloxyC1-6alkyl or polyhydroxy~C1-4alkylalkyl-;
Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from Cualkyl; and
Het17 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl!, C2-6cycloalkyl, hydroxy-C1-6alkyl-,
Jutalkyl or polyhydroxy-C1-6alkyl-;
\y»-
Het18 and Het19 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het18 and Het19 are optionally substituted with one or where possible two or more substituents selected from C1-6alkyl, Cs-cycloallcyl, hydroxy-Cialiyl-, C1-4alkyloxyC1-6alkyl or polyhydroxy-C1-6alkyl-;
Ar1, Ar3, Ar4 and Ar5 each independently represent phenyl optionally substituted with cyano, C1-4allcylsulfonyl-, Ciallcylsulfonylamino-, aminosulfonylamino-, hydroxy-C1-6alkyl, aminosulfonyl-, hydroxy-, Cwalkyloxy-
In particular those intermediates of formula (XXX) wherein one or more of the
following restrictions apply; i) X1 represents -O-; ii) X2 represents a direct bond, -NRn-d.2alkyl-, -NR1 l-CR2-,
-C1-2alkyl-, -O-Ci-aalkyl, -O- or~O-CH2-; iii) R1 represents hydrogen or halo; iv) R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-,
Het16-carbonyl- or Ar5; v) R18 represents hydrogen, C1-4alkyl!-, Ar4-C1-6alkyl or R18 represents C1-6alkyl
substituted with one or where possible two or more substituents selected from
C1-6alkyloxy- or Het2-;
vi) R1 1 represents hydrogen, Cwalkyl- or CiaJkyl-oxy-carbonyl-; vii) R12 represents Het14-C1-6alkyl, in particular morphoUnyl-Ciallcyl; viii) Het2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl
or pyrrolidinyl wherein said Het2 is optionally substituted with one or where
possible two or more substituents selected from hydroxy, amino or C1-4alkyl-;
n a ftirther embodiment Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with Cialiyl-, preferably methyl;
k) Het14 represents morpholinyl;
x) Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl;
xi) Ar4 represents phenyl;
xii) Ar5 represents phenyl optionally substituted with cyano.
It is also an object of the present invention to provide the use of an intermediate of formula (III) or (XXX) in the synthesis of a compound of formula (I).
The compounds of the present invention are useful because they possess pharmacological properties. They can therefore be used as medicines.
As described in the experimental part hereinafter, the growth inhibitory effect and anti-tumour activity of the present compounds has been demonstrated in vitro, in enzymatic assays on the receptor tyrosine kinase EGFR. In an alternative assay, the growth inhibitory effect of the compounds was tested on the ovarian carcinoma cell line SKOV3 using art known cytotoxicity assays such as LIVE/DEAD (Molecular Probes) orMTT.
Accordingly, the present invention provides the compounds of formula (I) and their pharmaceutically acceptable AT-oxides, addition salts, quaternary amines and stereochemically isomeric forms for use in therapy. More particular in the treatment or prevention of cell proliferation mediated diseases. The compounds of formula (I) and their pharmaceutically acceptable JV-oxides, addition salts, quaternary amines and the stereochemically isomeric forms may hereinafter be referred to as compounds according to the invention.
Disorders for which the compounds according to the invention are particularly useful are atherosclerosis, restenosis, cancer and diabetic complications e.g. retinopathy.
In view of the utility of the compounds according to the invention, there is provided a method for the treatment of an animal, for example, a mammal including humans, suffering from a cell proliferative disorder such as atherosclerosis, restenosis and cancer, which comprises administering an effective amount of a compound according to the present invention.
Said method comprising the systemic or topical administration of an effective amount of a compound according to the invention, to animals, including humans.
Due to their high degree of selectivity as EGFR inhibitors, the compounds of formula (I) as defined above, are also useful to mark or identify the Mnase domain within the receptor tyrosine kinase receptors. To this purpose, the compounds of the present invention can be labelled, in particular by replacing, partially or completely, one or more atoms in the molecule by their radioactive isotopes. Examples of interesting labelled compounds are those compounds having at least one halo which is a radioactive isotope of iodine, bromine or fluorine; or those compounds having at least one 1 lC-atom or tritium atom.
One particular group consists of those compounds of formula (I) wherein R* is a radioactive halogen atom. In principle, any compound of formula (I) containing a halogen atom is prone for radiolabeling by replacing the halogen atom by a suitable isotope. Suitable halogen radioisotopes to this purpose are radioactive iodides, e.g. 122I, 123I, 125I, 131I; radioactive bromides, e.g. 75Br, 76Br, 77Br and KBr, and radioactive fluorides, e.g. 18F. Hie introduction of a radioactive halogen atom can be performed by a suitable exchange reaction or by using any one of the procedures as described hereinabove to prepare halogen derivatives of formula (I).
Another interesting form of radiolabeling is by substituting a carbon atom by a nC-atom or the substitution of a hydrogen atom by a tritium atom.
Hence, said radiolabelled compounds of formula (I) can be used in a process of specifically marking receptor sites in biological material. Said process comprises the steps of (a) radiolabeling a compound of formula (I), (b) administering this radio-labelled compound to biological material and subsequently (c) detecting the emissions from the radiolabelled compound.
The term biological material is meant to comprise every kind of material which has a biological origin. More in particular this term refers to tissue samples, plasma or body fluids but also to animals, specially warm-blooded animals, or parts of animals such as organs.
When used in in vivo assays, the radiolabelled compounds are administered in an appropriate composition to an animal and the location of said radiolabelled compounds is detected using imaging techniques, such as, for instance, Single Photon Emission Computerized Tomography (SPECT) or Positron Emission Tomography (PET) and the like. In this manner the distribution of the particular receptor sites throughout the body can be detected and organs containing said receptor sites can be visualized by the
imaging techniques mentioned hereinabove. This process of imaging an organ by administering a radiolabelled compound of formula (T) and detecting the emissions from the radioactive compound also constitutes a part of the present invention.
In yet a further aspect, the present invention provides the use of the compounds according to the invention in the manufacture of a medicament for treating any of the aforementioned cell proliierative disorders or indications.
The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutical effect will be, of course, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated. A suitable daily dose would be from 0.01 nag/kg to 300 mg/kg body weight, in particular from 10 mg/kg to 100 mg/kg body weight A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with apharmaceutically acceptable carrier or diluent The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
!
The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18* ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water,
glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. Forparenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Ihjectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared hi which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetemuned quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
Experimental part
Hereinafter, the term "ADDP" is defined as l,r-(azodicarbonyl)bis-piperidine, "BuLr" is defined as butyl-lithium, "DCM" is defined as dichloromethane, "DEPE" is defined as diisopropyl ether, "DMF" is defined as JVdimernylformamide, "MeOH" is defined as methanol, "THF" is defined as tetrahydrofuran, "iPrOff' is defined as 2-propanol, "t-BuOff' is defined as 2-methyl-2-butanol, "AcOEt" is defined as ethyl acetate, "TFA" is defined as trifluoroacetic acid, "DL?EA"is defined as diisopropylethylamine
"HBTU" is defined as l-[bis(dimethylamino)methylene]-, hexafluorophosphate(l-), ljfy~benzotriazolium, 3-oxide, "(n-BuNT' is defined as tetrabutylammonium iodide, "NMP"is defined as l-methyl-2-pyrrolidinone and "Et3TST' is defined as JVTSr-diethylethanamine.


Example Ol - General description for the synthesis of compounds of formula 12
(Figure Removed)
imidazolinyl, piperidinyl, morpholinyl, pyrazolidinyl orpiperazinyl; n represents 0,1,2 or 3.
Reductive Animation.
To a solution of 1 (1 equiv.) and 2 (1 equiv.) in 1,2-dichIoroethane (3 mL/mmol), MgSO4 is added (1.5 equiv.) and the mixture is stirred at room temperature, for 90 minutes. To the resulting mixture NaBH(OAc)3 (1.1 equiv.) is added in three portions (one portion per hour), and the resulting mixture is stirred for additional 2 hours at room temperature. The reaction mixture is poured into a saturated solution of Na2CX>3 and extracted with dichloromethane (3x). The combined organic layers is washed with brine, dried over MgSC>4, filtered and concentrated. The crude product is purified by flash chromatography (SiQa, AcOEt/Hexanes mixture) to afford pure 3.
Reduction of the Nitro group.
To a solution of 3 (1 equiv,) in methanol (SmL/mmol), Pt/C is added (10% w/w) and the resulting mixture is placed under Ha atmosphere (balloon) and stirred at room temperature overnight (14 hours). The mixture is filtered through a short pad of celite and concentrated to dryness. In certain cases purification through flash chromatography is required to afford pure anilines of type 4.
Nucleophilic displacement.
To a stirred suspension of chlorocyano quinoline 5 (1.05 equiv) in iPrOH or t-BuOH (11 mL/mmol), 4 is added (1 equiv.). The mixture is allowed to react under reflux temperature under Nj for 6-8 hours. The reaction mixture is evaporated to dryness and the resulting residue is purified by flash-chromatography (SiOa, AcOEt/ Hexanes mixture) to afford pure 6.
Deacetylation.
Compound 6 is dissolved in MeOH/NHa 7N (8mL/mmol). To this solution, iPrOH (2 mL/mmol) is added and the reaction mixture stirred at room temperature for 30-120 minutes (TLC monitoring). The mixture is concentrated to dryness and the resulting product used in the next step without further purification.
Alkylation Reaction.
To a stirred solution of 7 in DMF (5 mL/mmol), CsaCOs (3 equiv.) is added followed by the alkylating reagent (2.5 equiv.). The reaction mixture is stirred at room . temperature overnight When neccessary, an additional 3 equiv. of CsaCOa and 2.5 equiv. of the alkylating reagent is added and the reaction mixture further stirred at room temperature until total completion of the reaction (TLC monitoring). The reaction mixture is partitioned between brine and AcOEt, and the layers separated. The organic layer is dried over MgSO4, filtered and evaporated. The residue is purified by flash-chromatography (AcOEt/n-hexanes) to afford pure 9.
Cleavage of the Boc group.
To a cooled (0°C) solution of 9 in CHaCk (3mL/mmoI), TFA (2mL/mmol) is added dropwise. The resulting mixture is warmed to room temperature and stirred for 1 -2 hours. A saturated solution of NaHCOa is added to the reaction mixture until basic pH is reached. The mixture is extracted with CHbCfe (2x). The combined organic layers are dried over MgSO4, filtered and concentrated to dryness. The resulting free aroine is obtained with enough purity to be used in the next step without further purification.
Saponificatton of the ester group.
To a solution of 10 inMeOH/H2O (10:1) is added LJOH'H2O (5 equiv.) and the reaction mixture is stirred at room temperature up to 2 hours. The solvent is evaporated under vaccuo and the residue is dissolved in DMF and filtered through a syntered glass funnel. The DMF is removed and the product used as such in the following reaction,
Cyclizatton reaction.
A solution of 11 (0.25 mmol, 1 equiv.) and DIPEA (6 equiv) in DMF (lOmL) are added dropwise to a solution of HBTU (3 equiv) in DMF (lOOmL/mmol of 11). The resulting mixture is stirred at room temperature for 1 hour. The solvent is evaporated and the product purified by reverse-phase HPLC.
By the above synthetic procedures, the following compounds are obtained:

(ethanediyMene)pyrido[4,3-Z>][6J,10,13]benzoxatriazacyclohexadecine-4-carbonittile (compound 1.1)
hexadecine-1-carbonitrile (compound 1.2)
7-cMoro-8-fluoro-21-methoxy41-me1hyI-13-axo-10,ll,12,1344,15,16,17-odahydro-5H- 1 , 1 9-(ethanediylidene)pyrido[4,3-6] [6, 1 , 10,1 3]benzoxatriazacyclohexadecine-4-carbonitrile (compound 1.3)
17-chloro-l 6-fluoro-20-methoxy-13-methyl-l l-oxo-8,9,10,1 1,12,13,14,19-octahydro-4,6-(ethanediylidene)pyrido[4,3-&][6, 1,9s12]benzoxatriazacyclopentadecine-l -carbo-nitrile (compound 1.4)
7-cMoro-8-fluoro42-isobutyl-21-methoxy-13-oxo-10,ll,12J3,14,15,16,17-oc1ahydro-5H-1 , 1 9-(ethanediylidene)pyrido[4,3-Z>][6, 1 , 1 0, 1 3]ben2oxatriazacyclohexadecine-4-carbonitrile (compound 1.5)
Example O2 - General description f (Figure Removed)

As used in scheme 10 hereinbefore; X represents halo, in particular chloro, fluoro or bromo; n represents 0, 1, 2 or 3; m represents 0, 1, 2 or 3.
Amide formation.
To a stirred solution of 1 (I equiv.) in CHaCfc (5 mL/mmol), diisopropyl carbodiimide (1 .05 equiv.) is added. The reaction mixture is stirred for 30 minutes at room temperature, then the amine 2 (1.05 equiv.) is added and stirring continued for another 30 minutes. The reaction mixture is then partitioned between IN citric acid and CEfeCla. The layers are separated and the organic layer dried over MgSO.4, filtered and evaporated to afford 3 with enough purity to be used in the next step.
Reduction of the Nitro group.
To a solution of 3 (1 equiv.) in MeOH (5mL/mmol), Pt/C is added (10% w/w) and the resulting mixture is placed under Ha atmosphere (balloon) and stirred at room temperature overnight (14 hours). The mixture is filtered through a short pad of celite and concentrated to dryness. In certain cases purification through flash chromatography is required to afford pure anilines of type 4.
Nucleophilic displacement.
To a stirred suspension of chlorocyano quinoline 5 (1.05 equiv.) in iPrOH (1 1 mL/mmol), 4 is added (1 equiv.) and a few drops of cone. HC1. The mixture is allowed to react under reflux temperature under Na for 6-8 hours. The reaction mixture is evaporated to dryness and the resulting residue purified by flash-chromatography z, AcOEt/Hexanes mixture) to afford pure 6.
Cleavage of the Boc group.
To a cooled (0°C) solution of 6 in CH2C12 (3mL/mmol), TFA (2mL/mmol) is added dropwise. The resulting mixture is allowed to warm to room temperature and stirred for 1 -2 hours. A saturated solution of NaHCOa is added to the reaction mixture until basic pH is reached. The mixture is extracted with CH2Cl2 (2x). The combined organic layers are dried over MgSC>4, filtered and concentrated to dryness. The resulting free amine is obtained with enough purity to be used in the next step without further purification.
Sulfonylation reaction.
To a cooled (0°C) solution of 7 (1 equiv.), in CH2C12 (2 mLAnmol), Et3N (1.5 equiv.), and DMAP (10% mol) are added. A solution of ortho-nilrobenzosulfonyl chloride (1.1 equiv.) in CE2Ck (1 mL/mmol of 7) is added dropwise. The reaction mixture is stirred at 0°C and allowed to warm to room temperature overnight IN HC1 is added until acidic pH is reached, and the layers separated. The organic layer is dried over MgSO4, filtered and evaporated. The resulting residue is purified by flash-chromatography (AcOEl/hexanes) to afford pure 9.
Deacetylation.
Compound 9 is dissolved in MeOH/NHs 7N (8rnL/rnmol).. To this solution, iPrOH (2 mL/mmol) is added and the reaction mixture stirred at room temperature for 30-120 minutes (TLC monitoring). The mixture is concentrated to dryness and the resulting product used in the next step without further purification.
Alkylation Reaction.
To a stirred solution of 10 in DMF (5 mL/mmol), CsaCOj (3 equiv.) are added followed by the alkylating reagent (2.5 equiv.). The reaction mixture is stirred at room temperature overnight. If neccessary, an additional 3 equiv. of Cs2CO3 and 2.5 equiv. of the alkylating reagent are added and the reaction mixture is stirred at room temperature until total completion of the reaction (TLC monitoring). The reaction mixture is partitioned between brine and AcOEt, and the layers are separated. The organic layer is dried over MgSC>4, filtered and evaporated. The residue is purified by flash-chromatography (AcOEt/n-hexanes) to afford pure 11.
Cyclization reaction.
A solution of 11 (1 equiv.) in MeCN (60 mL/mmol) is added dropwise at room temperature over a mixture of CsaCOs (5 equiv.) and (n-Bu)4NI (2 equiv.) in MeCN (30mL/mmoI). The reaction mixture is stirred at 65°C overnight. Upon completion of the reaction (LC monitoring), H2O is added. The resulting precipitate is collected by filtration and washed with EbO. The product is dried under vacuum at 65°C. The solid material is boiled in iPrOH. The solid material is filtered and dried.
Desulfonylation reaction.
A mixture of 12 (1 equiv.), thiophenol (1.2 equiv) and CsjCOj (3 equiv.) in DMF (45 mL/mmol of 12) is stirred at room temperature for 2 hours. The reaction mixture is quenched with ice-HaO and extracted with CHaCk/MeOH (90:10). The separated organic layer is dried over MgSC>45 filtered and evaporated. The product is purified by reverse-phase HPLC.
By the the above synthetic procedures, the following compounds are obtained:
7-brQmo-23-methoxy-12.oxo-10,ll,12,13,14,15,16,17,18J19-decahydro-5-l,21-(ethanediylidene)pyrido[4,3-f6,1,10,13JbenzoxatriazacycJooctadecine-4-carbonitriIe (compound 1.6)
7-chloro-23-methoxy-ll-oxo-10>ll,12,13,14,15,16,17,18,19-decahydro-5H-l,21-(ethanediylidene)pyrido[4,3-*][6,l,10,I4]benzoxatriazacyclooctadecine-4-carbonitrile (compound 2.1)
7-chloro-24-methoxy-12-oxo-5,105llJ12,13,14,15,16,17,18,19,20-dodecahydro-l,22-(ethanediylidene)pyrido[4,3-Z>][6,1,10,14Jbenzoxatriazacyclononadecine-4-carbonitrile (compound 2.2)
7-chloro-23-methoxy-12-oxo-10,n,12,13,14,15,l6,17,18,19-decahydro-5-l,21-
(eftanediylidene)pyrido[4,3-fe][6,l,10,131be
(compound 2.4)
Example Q3 - General description for the synthesiof compounds of formula 8
Scheme 11
(Figure Removed)
22-methoxy-14-oxo-11,12,13,14,15,16,17,18-octahydro-5J7-1,20-(ethanediylidene)r pyrido[3,4-jH][l, 10,6,15]berizod1oxadiazacyclohepladecme-carbonitrile (compound 2.3)
Nucleophilic displacement
To a stirred suspension of chlorocyano quinoline 2 (1.05 equiv.) in iPrOH (11 mL/mmol), is added 1 (1 equiv.) followed by EtsN (1 equiv). The mixture is heated to reflux under Na atmosphere for 6 hours. The reaction mixture is evaporated to dryness and the resulting residue purified by flash-chromatography (SiOa, AcOEt/Hexanes mixture) to afford pure 3.
Deacetylation.
Compound 3 is dissolved in MeOH/NH3 7N (8mL/inmol). To this solution, iPrOH (2 rnUmmol) is added and the reaction mixture stirred at room temperature for 30-120 minutes (TLC monitoring). The mixture is concentrated to dryness and the resulting product used in the next step without further purification.
Alkylation Reaction.
To a stirred solution of 4 in DMF (5 mL/mmol), CsjCCb (3 equiv.) is added followed by the alkylaung reagent (2.5 equiv.). The reaction mixture is stirred at room temperature overnight. The reaction mixture is partitioned between brine and AcOEt, and the layers separated. The organic layer is dried over MgSO4, filtered and evaporated. The residue is purified by flash-chromatography (AcOEt/n-hexanes) to afford pure 5.
Cleavage of the Hoc group
To a cooled (0°C) solution of 5 in CHfeCla (3mL/mmol), TFA (2mLtemol) is added dropwise. The resulting mixture is allowed to warm to room temperature and stirred for 1 -2 hours. A saturated solution of NaHCOa is added to the reaction mixture until basic pH is reached. The mixture is extracted with CHaCk (2x). The combined organic layers are dried over MgSO4, filtered and concentrated to dryness. The , resulting free amine is obtained with enough purity to be used in the next step without further purification.
Saponification of the ester group
To a solution of 6 inMeOH/H2O (10:1), LiOH'H2O (5 equiv) is added and the reaction mixture is stirred at room temperature up to 2 hours. The solvent is evaporated under vaccuo and the residue is dissolved in DMF and filtered through a syntered glass funnel. The DMF is removed and the product used as such hi the following reaction.
Cyclizafion reaction
A solution of 7 (0.25 mmol, 1 equiv.) and DEPEA (6 equiv) in DMF (lOmL) is added dropwise to a solution of HBTU (3 equiv.) in DMF (lOOmL/mmol of 7). The
resulting mixture is stirred at room temperature for 1 hour. The solvent is evaporated and the product purified by reverse-phase HPLC.

Ikample Q4 - General description for the synthesis of compounds of formula 6
(Figure Removed)
17-chloro-16-fluoro-20-methoxy-8,9,10,ll,12,13,14,19-octahydro-4,6-(ethane-diyHdene)pvrido[4,3-][6,lJ2]benzoxadiazacyclor«nladecine-l-carbonitrile (compound 2.5)
Nucleophilic displacement
To a stirred solution of chlorocyano quinoline 2 (1.05 equiv.) in t-BuOH/DMF 12:1(11 mL/mmol), 1 is added. The mixture is warmed to 80°C under Na for 6 hours.
The reaction mixture is evaporated to dryness and the resulting residue is stirred in MeCN for 1 hour. A solid precipitate is collected by filtration, washed with MeCN and dried to afford pure 3 in 63% yield.
Chlorination reaction
Methyl sulfonyl chloride (9.4 mL) is added to a solution of 3 (12.50 mmol) in 50 mL of NMP at room temperature. The reaction mixture is then stirred at 90°C for 1 hour. The reaction mixture is then poured out into 300 mL of H2O, the aqueous layer extracted with AcOEt (3x100 mL). The combined organic layers are washed with BbO (2x100 mL), and finally the organic layer is dried, filtered and concentrated under reduced pressure. The resulting residue is purified by column chormatograpby affording pure 4 in 90% yield,
Cyclization reaction
Compound 4 (5.0 mmol) andKaCOs (5 equiv) are stirred in 83 mL of DMA/HaO (1:1) at 150°C in a pre-heated sealed reactor for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue purified by reverse-phase HPLC to afford 5.
Removal of the CBz group
To a solution of 5 (1 equiv) in MeOH (5mL/mmol), Pt/C is added (10% w/w) and the resulting mixture is placed under Hi atmosphere (balloon) and stirred at room temperature overnight (14 hours). The mixture is filtered through a short pad of celite and concentrated to dryness. The residue is purified by reverse-phase HPLC to afford pure 6.
Example OS - General description for the synthesis of compounds of formula 10
Scheme 13
(Figure Removed)
7-chloro-8-fluoro-21-methoxy-ll-methyl-10,ll,12,13,14,15,16917-octahydro-5/f-l,19-(e1hanediyUdene)pyrido[4>3-fe][6sl,l3]benzoxadiazacyclohexadecme-4-carbonitrile (compound 2.6)
Reductive Animation
To a solution of 1 (1 equiv.) and 2 (1 equiv.) in 1,2-dichloroethane (3 mL/mmol), MgSO4 is added (1.5 equiv.) and the mixture stirred at room temperature for 90 minutes. To the resulting mixture NaBH(OAc)3 (1.1 equiv.) is added in three portions (one portion per hour), and the resulting mixture stirred for additional 2 hours at room temperature. The reaction mixture is poured into a saturated solution of NaaCOj and extracted with CHaCla (3x). The combined organic layers are washed with brine, dried over MgSO4, filtered and concentrated. The crude product is purified by flash chromatography (SiOa, AcOEt/Hexanes mixture) to afford pure 3.
Reduction of the Nitro group
5 equiv. of a 0.5 M solution of NKUCl in H2O are added to a 0.1M solution of the nitro derivative 3 (1 equiv.) in toluene at room temperature. Iron powder (5 equiv.) are added while stirring vigorously. The reaction mixture is stirred at reflux temperature for 1 hour and then cooled to room temperature, filtered through a celite pad and the organic layer separated, dried over MgSC>4 and evaporated under reduced pressure. The aniline 4 is obtained quantitatively and is pure enough to be used in the next step without further purification.
Nucleophilic displacement
To a stirred suspension of chlorocyano quinoline 5 (1.05 equiv.) in iPrOH (11 mL/mmol), 4 is added (1 equiv.). The mixture is allowed to react under reflux temperature under N2 for 6-8 hours. The reaction mixture is evaporated to dryness and the resulting residue purified by flash-chromatography (SiOa, AcOEtfHexanes mixture) to afford pure 6.
Deacetylation
Compound 6 is dissolved in MeOH/NHa 7N (8mL/mmol). To this solution, iPrOH (2 mL/mmol) is added and the reaction mixture stirred at room temperature for 30-120 minutes (TLC monitoring). The mixture is concentrated to dryness and the resulting product used in the next step without farther purification.
Alkylation Reaction
To a stirred solution of 7 in DMF (5 ml/mmol), CsiCOs (3 equiv.) is added followed by the alkylating reagent (2.5 equiv.). The reaction mixture is stirred at room temperature overnight.
Ring Closing Metathesis
To a solution of 8 (1 equiv.) in anh. CHaCk (100 mL/mmol), Grubbs's Catalyst second generation is added (20% mol). The resulting mixture is refluxed with stirring under Na atmosphere for 4 hours. After that time, additional catalyst (20% mol,) is added and the mixture is stirred for an additional 2 hours, by which time the reaction is essentially complete. The solvent is removed under reduced pressure and the resulting
crude material is purified by flash-chromatography (AcOEi/hexanes) to yield pure product 9.
Hydrogenation of the double bond
To a solution of 9 (1 equiv.) in MeOH (5mL/mmol), Pt/C is added (10% w/w) and the resulting mixture is placed under Efe atmosphere (balloon) and stirred at room temperature overnight (14 hours). The mixture is filtered through a short pad of celite and concentrated to dryness. The residue is purified by reverse-phase HPLC to afford pure 10.
A. Preparation of the intermediates c?
Example Al
a) Preparation of 1-pentanol, 5-[[(4-bromo-2-nitrophenyl)methyl]amino]- (intermediate 1)
A solution of 4-bromo-2-nitro-benzaldehyde, (0.013 mol), 5-amino-1-pentanol (0.013 mol) and titanium, tetrakis (2-propanolate) (0.014 mol) in ethanol (15 ml) was stirred at room temperature for 1 hour, then the reaction mixture was heated to 50 °C and stirred for 30 min. The mixture was cooled to room temperature and sodium hydroborate (0.013 mol) was added portionwise. The reaction mixture was stirred overnight and then poured out into ice water (50 ml). The resulting mixture was stirred for 20 min., the formed precipitate was filtered off (giving Filtrate (I)), washed with water and stirred in DCM (to dissolve the product and to remove it from the Ti-salt). The mixture was filtered and then the filtrate was dried (MgSO/O and filtered, finally the solvent was ' evaporated dry. Filtrate (I) was evaporated until ethanol was removed and the aqueous concentrate was extracted 2 times with DCM. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporated dry, yielding 3.8g (93 %) of intermediate 1.
b) Preparation of carbamic acid, [(4-bromo-2-nitrophenyl)methyl](5-hydroxypentyl)-, 1,1 -dimethylethyl ester (intermediate 2)
A solution of intermediate 1 (0.0032 mol) in DCM (20 ml) was stirred at room temperature and a solution of dicarbonic acid, bis(l, 1 -dimethylethyl) ester (0.0032 mol) in DCM (5 ml) was added dropwise. The reaction mixture was stirred for 1 hour at room temperature and washed 2 times with water. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporated dry, yielding intermediate 2.
c) Preparation of carbamic acid, [5-(acetyloxy)pentyl][(4-bromo-2-nitroplienyl)metliyl]-,
1,1-dimethylethyl ester (intermediate 3)
A solution of intermediate 2 (0.0032 mol) and pyridine (0.032 mol) in acetic acid anhydride (15 ml) was stirred at room temperature for 16 hours, then the solvent was evaporated under reduced pressure and co-evaporated with toluene. The residue was used as such in the next reaction step, yielding 1.47g (100 %) of intermediate 3.
d) Preparation of carbamic acid, [5-(ac«1yloxy)pen1yl][(2-amino-4-bromo-phenyl)-
methyl]-, 1,1-dimethylethyl ester (intermediate 4)
A mixture of intermediate 3 (0.0033 mol) in THF (50 ml) was hydrogenated with Pl/C 5% (0.5g) as a catalyst in the presence of thiophene solution (0.5ml) After uptake of Ha (3 equiv.), the catalyst was filtered off and the filtrate was evaporated, yielding intermediate 4.
Example A2
a) Preparation of benzoic acid, 2-amino-4-methoxy-5-(phenyImethoxy)-, methyl
ester (intermediate 5)
A mixture of 4-methoxy-2-nitro-5-(phenyhnethoxy)- benzoic acid, methylester, (0.166 mol) and triethylamine (0.198 mol) in THF (400 ml) was hydrogenated with Pi/C (5 g) as a catalyst in the presence of thiophene in DIPE (4 ml). After uptake of hydrogen (3 equivalents), the catalyst was filtered off and the filtrate was evaporated. The residue was treated with DIPE (300 ml) and stirred for 3 hours, Ihen the resulting precipitate was filtered off and dried in a vacuum oven, yielding 45.9g (96 %) of intermediate 5.
b) Preparation of 3-q\molmecarbomtrile, 4-hydroxy-7-methoxy-6-(phenyl-
methoxy)- (intermediate 6)
A mixture of intermediate 5 (0.029 mol) and 1,1-dimethoxytrimemyIamine, (0.058 mol) in DMF (30 ml) was stirred and refluxed for 2.5 hours, then the solvent was evaporated and co-evaporated with toluene (2 x), giving Residue (T). A solution of n-BuLi, 2.5 M in hexane (0.058 mol) in THF (40 ml) was stirred and cooled to -75 °C and acetonitrile (0.058 mol) was added dropwise in 30 min. After 15 min. a solution of Residue (I) in THF (40 ml) was added dropwise and the the reaction was quenched
with acetic acid (0.058 mol) at -75 °C, then the mixture was allowed to reach room temperature and was diluted with water (50 ml). The organic solvent (TIIF) was evaporated and the aqueous concentrate was diluted with 2-propanol (10 ml). This mixture was stirred for 1 hour and then the resulting precipitate was filtered and air-dried, yielding 4.4g of intermediate 6. The filtrate was evaporated and then the residue was treated with water and DCM/MeOH (90/10). The resulting mixture was stirred for 15 minutes and the obtained solids were collected and air-dried, yielding 1.8g of intermediate 6. Overall Yield: 6.2g (70.4 %).
c) Preparation of 3-quinohnecarbonitrile, 4,6-dihydroxy-7-methoxy- (intermediate 7)
A mixture of intermediate 6 (0.016 mol) in triethylamine (3 ml) and THF was hydrogenated with Pd/C (1.0 g) as a catalyst. After uptake of Hj (1 equivalent), the catalyst was filtered off and the filtrate was evaporated, yielding 2.8g of intermediate 7 (used as such in the next reaction step).
d) Preparation of 3-quinolinecarbonitrile, 6-(acetyloxy)-4-hydroxy-7-methoxy-
(intermediate 8)
A mixture of intermediate 7 (0.011 mol) and pyridine (0.016 mol) in acetic anhydride (30 ml) was heated for 1 hour on an oil bath at 95°C, then the reaction mixture was allowed to reach room temperature and was stirred overnight. The solvent was evaporated and then the residue was treated with DEPE (30 ml) and the mixture was
I
stirred for 2 hours. The resulting precipitate was collected and dried, yielding 2.58g (90.8 %) of intermediate 8.
e) Preparation of 3-quin.olinecarbonitrile, 6-(acetyloxy)-4-chloro-7-me1hoxy-
(intermediate 9)
A mixture of intermediate 8 (0.01 mol) and DMF (3 drops) in thionylchloride (25 ml) was heated for 2 hours on an oil bath at 80°C, then the solvent was evaporated. The residue was treated with DIPE and the mixture was stirred for 1 hour. The resulting solids were filtered off and air-dried. The residue (2.7g) was dissolved in DCM and washed with NaHCC1-4 solution. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporated, yielding 2.5g of intermediate 9.
r) Preparation of carbamic acid, f[2-[[6-(aceryloxy)-3-cyano-7-methoxy-4-qimolmyl]ammo]-4"-bromophenyl]methyl][5-(acetyloxy)pentyl]-, 1,1-dimethylethyl ester (intermediate 10)
A mixture of intermediate 9 (0.0018 mol) and intermediate 4 (0.0018 mol) in 2-propanol (20 ml) was heated overnight on an oil baft at 65°C, then the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: DCM/MeOH 99.7/0.3). One fraction was collected and the column was eluted again with DCM/MeOH/THF (90/5/5). Another fraction was collected and purified farther by column chromatography over silica gel (eluent: DCM/MeOH gradient). The producjt fractions were collected and the solvent was evaporated, yielding 0.61g (50.6 %) of intermediate 10.
g) Preparation of carbamic acid, [[4-bromo-2-[(3-cyano-6-hydroxy-7-methoxy-4-quinolmyl)aimo]phenyl]methyy(5-hydroxvpentyl)-, 1,1-dimethylethyl ester (intermediate 11)
A stirring solution of intermediate 10 (0.000896 mol) in MeOH (20 ml) was treated with a solution of potassium carbonate (0.0018 mol) in water (5 ml). The reaction mixture was stirred overnight at room temperature and then neutralised with acetic acid until pH: 7. The solvent was evaporated. The residue was diluted with DCM and washed with water. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporate, yielding 0.38g (73.1 %) of intermediate 11, melting point 114.3-136.2 °C.
B. Preparation of the compounds Example Bl
a) Preparation of 4,6-ethanediylidenepyrido[4,3-£>]f6,l,12Jbenzoxadiazacyclo-pentadecine-13(8/0-carboxylic acid, 17-bromo-l-cyano-9,10,l 1,12,14,19-hexa-hydro-20-tnethoxy-, 1,1-dimethylethyl ester (compound 1)
A mixture of intermediate 11 (0.000649 mol) and ADDP (0.00094 mol) in THF p.a. (40 ml) was treated for 1 hour with triburylphosphine (0.00094 mol) and men extra ADDP (0.00094 mol) and tributylphosphine (0.00094 mol) were added. After 16 hours, the solvent was partially evaporated and the resulting concentrate was filtered and the filtrate evaporated. The residue was dissolved in THF p.a. (40 ml) and then ADDP (2
equivalents) was added, followed by tributylphosphine (2 equivalents). The resulting mixture was purified by reversed phase high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.0955g (26.0 %) of compound 1.
b) Preparation of 4,6-ethanediylidenepyridot4,3-i][6,l,12]benzoxadiazacyclo-pentadecine-1 -carbonitrile, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-, monohydrochloride (compound 2)
A solution of compound 1 (0.00012 mol)in MeOH (5 ml) was treated with HC1/2-propanol (6N) (1ml) and the reaction mixture was stirred over the weekend. The resulting precipitate was collected and dried an a vacuum oven, yielding 0.0197 g of compound 2, isolated as a monohydrochloric acid salt.
C, Pharmacological examples
Example C.I : in vitro inhibition of EGFR
The in vitro inhibition of EGFR was assessed using either the Flash Plate technology or the glass-fiber filter technology as described by Davies, S.P. et al., Biochem J. (2000), 351; p.95-105. The Flash Plate technology is generally described by B.A. Brown et al in High Throughput Screening (1997), p.317-328. Editor(s): Devlin, John P. Publisher: Dekker, New York, N. Y.
In the Flash Plate EGFR kinase reaction assay, a kinase substrate consisting of biotinylated poly(L-glutamic acid-L-tyrosine) (poly(GT)biotin), is incubated with the aforementioned protein in the presence of (33P) radiolabeled ATP. (33P) phosporylation of the substrate is subsequently measured as light energy emitted using a streptavidin-coated Flash Plate (PerkinElmer Life Sciences) by trapping and quantifying the binding of the biotin tagged and radiolabeled substrate.
Detailed description
The EGFR kinase reaction is performed at 30°C for 60 minutes in a 96-well microtiter FlashPlate (PerkinElmer Life Sciences). For each of the tested compounds a foil dose response I.IOM to 1.10"10M has been performed. IRESSA® and Tarceva™ (erlotinib) were used as reference compounds. The 100 nl reaction volume contains 54.5 mM TrisHCl pH 8.0,10 mM MgCl2, lOOM Na3VO4,5.0 uM unlabeled ATP, ImM DTT,
0.009% BSA, 0.8 fid AT33P, 0.35 ug/well poly(GT)biotin and 0.5 ug EGFR-kinase
domain/well.
The reaction is stopped by aspirating the reaction mixture and washing the plate 3x
with 200 ul wash/stop buffer (PBS +100 mM EDTA). After the final wash step 200 u.1
of wash/stop buffer was added to each well and the amount of phosphorylated (33P)
Poly(GT)biotin determined by counting (30 sec/well) in amicrotiterplate scintillation
counter.
In the glass-fiber filter technology EGFR kinase reaction assay, a kinase substrate consisting of poly(L-glutamic acid-L-tyrosine) (poly(GT)), is incubated with the aforementioned protein in the presence of (33P) radiolabeled ATP. (33P) Phosporylation of the substrate is subsequently measured as radioactivity bound on a glassfiber-filter.
Detailed description
The EGFR kinase reaction is performed at 25°C for 10 minutes in a 96-well
microtiterplate. For each of the tested compounds a full dose response 1.1 OM to 1.10"
10M has been performed. IRESSA® and Tarceva™ (erlotinib) were used as reference
compounds. The 25 ul reaction volume contains 60 mM TrisHCl pH 7.5, 3 mM
MgCfe, 3 mM Mn C12,3 |iM Na3VO4, 50 ug/ml PEG20000, 5.0 uM unlabeled ATP,
liuMDTT, 0.1 M,CSAT33P, 62.5 ng/well poly(GT) and 0.5 ug EGFR-kinase
domain/well.
The reaction is stopped by adding 5 ul of a 3% phosphoric acid solution. 10 ul of the
reaction mixture is then spotted onto a Filtermat A filter (Wallac) and washed 3 times
for 5 min. in 75 mM phosphoric acid and 1 time for 5 min. hi methanol prior to drying
and quantification on the Typhoon (Amersham) using a LE phosphorage storage
screen.
Example C.2: Serum starved proliferation assay on the ovarian carcinomaJSKOV3 cells The ovarian carcinoma cell line (SKOV3) was used in an epidermal growth factor stimulated cell proliferation assay, to assess the inhibitory effect of the compounds on EGF in whole cells.
In a first step the SKOV3 cells were incubated for 24 hours in the presence of 10% PCS serum, hi the second step the cells were incubated with the compounds to be tested in a serum free condition (37 °C and 5% (v/v) CCh) and subsequently stimulated for 72 hours with EGF at a final concentration of 100 ng/ml. The effect of the compounds on the EGF stimulation was finally assessed in a standard MTT cell viability assay.

The following table provides the pIC50 values of the compounds according to the invention, obtained using the above mentioned kinase assays.
(Table Removed)
D. Composition examples
The following formulations exemplify typical pharmaceutical compositions suitable for
systemic administration to animal and human subjects in accordance with the present
invention.
"Active ingredient" (A.I.) as used throughout these examples relates to a compound of
formula (I) or a pharmaceutically acceptable addition salt thereof.
Example P. 1 : film-coated tablets
A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and thereafter humidified with a solution of sodium dodecyl sulfete (5 g) andpolyvinyl-pyrrolidone (10 g) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient. Coating
To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in CH2C12 (150 ml). Then there were added CH2C12 (75 ml) and 1,2,3-propanetriol (2.5 ml). Polyethylene glycol (10 g) was molten and dissolved in dicMoromethane (75 ml). The latter solution was added to the former and then there were added magnesium octadecanoate (2.5 g), polyvinyl-pyrrolidone (5 g) and concentrated color suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture hi a coating apparatus.













WE CLAIM:
1. 3-Cyano-quinoline compounds as kinase inhibitors of formula:
(Formula Removed)
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereocbemically isomeric forms thereof, wherein
Z represents O,NH or S;
Y represents -C3-9alkyl-, -C3-9alkenyl-, -C1-5alkyl-oxy-C1-5alkyl-,
-C1-5alkyl-NR12-C1-5alkyl-,-C1-5alkyl-NR13-CO-C1-5alkyl-
-C1-5alkyl-CO-NR14-C1-5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-,
-CO-NH-C1-6alkyl-, -NH-CO-C1-6atkyl,t -CO-C1-7alkyl-, -C1-7alkyl-CO-,
C1-6alkyl-CO-C1-6alkyl,-C1-2alkyl-NH-CO-CH2R15-NH-; X1 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO- C1-2alkyl-, NR10,
-NR10-C1-2alkyl-, NR16-CO-, NR15-CO-C1-2alkyl, -O-N=CH- or C1-2alkyl; X2 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO- C1-2alkyl-, NR11,
NR11-C1-2alkyl-, NR17-CO-, NR17-CO-C1-4alkyl, Het20-C1-2alkyl, -O-N=CH- or C1-
2alkyl; R1 represents hydrogen, cyano, halo, hydroxy, formyl, C1-6alkoxy-, C1-6alkyl-,
C1-6alkoxy- substituted with halo,
C1-4alkyl substitated with one or where possible two or more substituents selected from hydroxy or halo; R2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het16-carbonyl-,
C1-4alkyloxycarbonyl-, C1-4alkylearbonyl-, aminocarbonyl-,
mono-or di(C1-4alkyl)aminocarbonyl-, Het1, formyl, C1-4alkyl-, C2-6alkynyl-,
C3-6cycloalkyl-, C3-6cycloalkyloxy-, C1-6alkoxy-, Ar5, Ar1-oxy-, dibydroxyborane ,
C1-6alkoxy- substituted with halo,
C1-4alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR4R5,
C1-4alkylcarbonyl- wherein said C1-4alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C1-4alkyl-oxy-;
R3 represents hydrogen, hydroxy, Ar3-oxy, Ar4-C1-4alkyloxy-, C1-4alkyloxy-,
C2-4alkenyloxy- optionally substituted with Het12 or R3 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy-, hydroxy, halo, Het2-, -NR6R7, -carbonyl- NR8R9 or Het3-carbonyl-;
R6and R5 are each independently selected from hydrogen or C1-4alkyl;
R6 and R7 are each independently selected from hydrogen, C1-4alkyl, Het3,
aminosulfonyl-, mono- or di (C1-4alkyl)-aminosulfonyl, hydroxy-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl-, hydroxycarbonyl-C1-4alkyl-, C3-6cycloalkyl, Hct9-carbonyl-C1-4atkyl-, Het10-carbonyl-, polyhydroxy-C1-4alkyl-, Het11-C1-4alkyl- or Ar2-C1-4alkyl-;
R8 and R9 are each independently selected from hydrogen, C1-4alkyl, C3-6cyeloalkyl, Het4, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl-or polyhydroxy-C1-4alkyl-;
R10 represents hydrogen, C1-4alkyl, Het5, Het6-C1-4alkyl-, C2-4alkenylcarbonyl-
optionally substituted with Het7-C1-4alkylaminocarbonyl-, C2-4alkenylsulfonyl-, C1-4alkyloxyC1-4alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-4alkyloxy-;
R11 represents hydrogen, C1-4alkyl, C1-4alkyl-oxy-carbonyl-, Het17, Het13-C1-4alkyl-, C2-4alkenylcarbonyl- optionally substituted with Het19-C1-4alkylaminocarbonyl-, C2-4alkenylsulfonyl-, C1-4alkyloxyC1-4alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-4alkyloxy-;
R12 represents hydrogen, C1-4alkyl, Het13, Het14-C1-4alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C1-4alkyloxy-;
R13andR14 are each independently selected from hydrogen, C1-4alkyl, Het115-C1-4alkyl-or C1-4alkyloxyC1-4alkyl-;
R15 represents hydrogen or C1-4alkyl optionally substituted with phenyl, indolyl,
methylsulfide, hydroxy, thiol, hydroxyphenyl, aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino;
R16 and R17 are each independently selected from hydrogen, C1-4alkyl, Het21 -C1-4alkyl or C1-4alkyloxyC1-4alkyl;
Het represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het1 is optionally substituted
ammo, C1-4alkyl, hydroxy-C1-4alkyl-, phenyl, phenyl-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl- mono- or di(C1-4alkyl)amino- or amino-carbonyl-;
Het2 represents a heterocycie selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het2 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C1-4alkyl-, hydroxy-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl-, hydroxy-C1-4alkyl-oxy-C1-4alkyl-, mono- or di(C1-4alkyl)amino-, mono- or di(C1-4alkyl)amino-C1-4alkyl-, amrnoC1-4alkyl-, mono- or di(C1-4alkyl)amino-sulfonyl-, aminosulfonyl-;
Het3, Het4 and Het8 each independently represent a heterocycie selected from
morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxoknyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridjnyl or pyrrolidinyl wherein said Het3, Het4 or Het8 is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C1-4alkyl-, C3-6cycloalkyl-C1-4alkyl-, aminosulfonyl-, mono- or di(C1-4alkyl)aminosulfonyl or amino-C1-4alkyl-;
Het5 represent a heterocycie selected from pyrrolidinyl or piperidinyl wherein said Het5 optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het6 and Het7 each independently represent a heterocycie selected from morpholinyl, pyrrolidinyi, piperazinyl or piperidinyl wherein said Het6 and Het7 are optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het9 and Het10 each independently represent a heterocycie selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyi wherein said Het9 or Hct10 is optionally substituted C1-4alkyl, C3-6cycloalkyl-C1-4alkyl- or ammo-C1-4alkyl-;
(Formula Removed)
represents a heterocycie selected from indolyl or
Het12 represents a heterocycie selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyi, thiomorpholinyl or dithianyl wherein said Het12 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C1-4alkyl-, hydroxy-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl-,
hydroxy-C1-4alkyl-oxy-C1-4alkyl-, mono- or di(C1-4alkyl)amino- or mono- or di(C1-4alkyl)amino-C1-4allkyl-;
Het13 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said Het13 is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4allkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het14 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het14 is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4allkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het15 and Hct21 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycles are optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C1-4alkyl; and
Het17 represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said Het17 is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-;
Het18 and Het79 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het18 and Het'9 are optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alky 1-;
Het20 represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolyl or pyrazolidinyl wherein said Het20 is optionally substituted with one or where possible two or more substituents selected from C1-4alkyl, C3-6cycloalkyl, hydroxy-C1-4alkyl-, C1-4alkyloxyC1-4alkyl or polyhydroxy-C1-4alkyl-; and
Ar1, Ar2, Ar3, Ar4 and Ar5 each independently represent phenyl optionally substituted with cyano, C1-4alkylsulfonyl-, C1-4alkylsulfonylamino-, aminosulfonylamino-, hydroxy-C1-4alkyl, aminosuifonyl-, hydroxy-, C1-4alkyloxy- or C1-4alkyl,
2. The compound as claimed in claim 1 wherein:
Z represents NH;
Y represents -C3-9alkyl-, -C2-9alkenyl-, -C1-5alkyl-oxy-C1-5alkyl-,
-C1-5alkyl-NR12-C1-5alkyl-, -C1-5alkyl-NR13-CO-C1-5alkyl-, -C1-6alkyl-NH-CO-,
-CO-C1-7alkyl- -C1-7alkyl-CO- or C1-6alkyl-CO-C1-6alkyl; X1 represents O, -O-C1-2alkyl-, -G-N=CH-, NR16CO, -NR16-CO-C1-2alkyl-, NR10 or
-NR10-C1-2alkyl-; in a particular embodiment X1 represents -O, -O-CH2-, NR10 or
-NR10-C1-2alkyl-; X2 represents a direct bond, O, -O-C1-2alkyl-, -O-N=CH-, Het20-C1-4alkyl, C1-2alkyl,
NR17-CO, -NR17-CO-C1-2alkyl-,NR11 orNR11-C1-2alkyl-; in a particular
embodiment X1 represents a direct bond, -O-N=CH-, -NR11-C1-2alkyl-,
-NR11-CH2-,Het20-C1-2alkyl,NR17-CO, -NR17-CO-C1-2alkyl- -C1-2alkyl-,
-O-C1-2alkyl, -O- or -O-CH2-; Rl represents hydrogen, cyano, halo or hydroxy, preferably halo; R2 represents hydrogen, cyano, halo, hydroxy, hydroxyearbonyl-, C1-
4alkyloxycarbonyl-;,Het16-carbonyl-, C2-6alkynyl-, Ar5 or Het1;
R3 represents hydrogen, hydroxy, C1-4alkyloxy-, Ar4-C1-4alkyloxy or R3 represents
C1-4alkyloxy substituted with one or where possible two or more substiiuents
selected from C1-4alkyloxy- or Het2-; R10 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R11 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R12 represents Het14-C1-4alkyl, in particular moroholinyl-C1-4alkyl; R16 represents hydrogen, C1-4alkyl-, Het21-C1-4alkyl or C1-4alkyl-oxy-C1-4alkyl; in
particular R16 represents hydrogen or C1-4alkyl; R17 represents hydrogen, C1-4alkyl-, Het21-C1-4alkyl or C1-4alkyl-oxy-C1-4alkyl; in
particular R16 represents hydrogen or C1-4alkyl; Het1 represents thiazolyl optionally substituted amino, C1-4alkyl, hydroxy-C1-4alkyl-,
phenyl, phenyl-C1-4alkyl-, C1-4alkyl-oxy-C1-4alkyl- mono- or di(C1-4alkyl)amino-
or amino-carbonyl-; Het represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C1-4alkyl-;
In a further embodiment Hot2 represents a heterocycle selected from morpholinyl
or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl; Het14 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het14 is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C1-4alkyl-;
Het16 represents a heterocycie selected from piperidinyl, morpholinyl or pyrrolidinyl; Hct20 represents; a heterocycie selected from pyrrolidinyl, 2-pyrrolidinyl or piperidinyl; Het21 represents a heterocycie selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het21 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C1-4alkyl-; Ar4 represents phenyl optionally substituted with cyano, hydroxy-, C1-4alkyloxy or
C1-4alkyl; Ar5 represents phenyl optionally substituted with cyano, hydroxy, C1-4alkyloxy or
C1-4alkyl.
3. The compound as claimed in claim 1 wherein:
Z represents NH; Y represents -C3-9alkyl-, -C1-5alkyl-NR12-C1-5alkyl-, -C1-5alkyl-NR13-CO-C1-5alkyl-,
-C1-6alkyl-NH-CO- or-CO-NH -C1-2alkyl-; X1 represents a direct bond, NR10, -NR10-C1-2alkyl-, -NR10-CH2-, -C1-2alkyl-,
-O-C1-2alkyl, -O- or -O-CH2-; X2 represents a-O-, NR11, NR17-CO, NR17-COC1-2alkyl or Het20-C1-2alkyl; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-,
Het16-carbonyi- or Ar5; R3 represents hydrogen, hydroxy, C1-4alkyloxy-, Ar4-C1-4alkyloxy or R3 represents
C1-4alkyloxy substituted with ooe or where possible two or more substituents
selected from C1-4alkyloxy- or Het2-; R10 represents hydrogen;
R11 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R12 represents Het14-C1-4alkyl, in particular morphaolinyl-C1-4alkyl; R13 represents hydrogen; R17 represents hydrogen; Hct2 represents a heterocycie selected from morpholinyl, piperazinyl piperidinyl or
pyrrolidinyl wherein said Het2 is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C1-4alkyl-;
In a -further embodiment Het2 represents a heterocycie selected from morpholinyl
or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl; Het14 represents morpholinyl;
Het16 represents a heterocycie selected from morpholinyl or pyrrolidinyl;
Het20 represents pyrrolidinyl or piperidinyl;
Ar4 represents phenyl;
Ar5 represents phenyl optionally substituted with cyano.
4. The compound as claimed in any one of claims 1 to 3 wherein the R1 substituent is at
position 4', the R2 substituent is at position 5' and the R3 substituent at position 7 of the structure
of formula (I).
5. Compound as claimed in any one of claims 1 to 4 as and when used in the preparation of
medicament for treating cell proliferative disorders such as atherosclerosis, restenosis and
cancer.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and. as active ingredient, an effective kinase inhibitory amount of a compound as described in any one of the claims 1 to 4.
7. A process for preparing a compound as claimed in claims 1 to 4, comprising:
a) coupling the known 6-acctoxy-4-chloro-3-cyano- quinolines of formula (II) with the suitable substituted anilines of formula (EH) to furnish the intermediates of formula (IV), and deprotecting the intermediates of formula (TV) followed by ring closure under suitable conditions
(Formula Removed)
V = protective group such as for example methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl
R18 represents Ar3, Ar4-C1-4alkyl C1-4alkyl, C2-6alkenyl optionally substituted with Het12 or R18 represents C1-4alkyl substituted with one or where possible two or more substituents selected from C1-4lkyloxy, hydroxy, halo, Het7', NR7R8, NR9R10-carbonyl or Het3-carbonyl, wherein Ar3, Ar4, Het12, Het2, R7, E8, R9, R10 and Het3 are defined as for the compounds of formula (I)

Documents:

3467-DELNP-2006-Abstract-(25-06-2010).pdf

3467-delnp-2006-abstract.pdf

3467-DELNP-2006-Claims-(25-06-2010).pdf

3467-delnp-2006-claims.pdf

3467-DELNP-2006-Correspondence-Others-(25-06-2010).pdf

3467-DELNP-2006-Correspondence-Others-(28-06-2010).pdf

3467-delnp-2006-correspondence-others-1.pdf

3467-delnp-2006-correspondence-others.pdf

3467-DELNP-2006-Description (Complete)-(25-06-2010).pdf

3467-delnp-2006-description (complete).pdf

3467-DELNP-2006-Form-1-(25-06-2010).pdf

3467-delnp-2006-form-1.pdf

3467-delnp-2006-form-18.pdf

3467-DELNP-2006-Form-2-(25-06-2010).pdf

3467-delnp-2006-form-2.pdf

3467-DELNP-2006-Form-3-(25-06-2010).pdf

3467-DELNP-2006-Form-3-(28-06-2010).pdf

3467-delnp-2006-form-3.pdf

3467-delnp-2006-form-5.pdf

3467-DELNP-2006-GPA-(25-06-2010).pdf

3467-delnp-2006-gpa.pdf

3467-delnp-2006-pct-210.pdf

3467-delnp-2006-pct-237.pdf

3467-delnp-2006-pct-304.pdf

3467-DELNP-2006-Petition 137-(25-06-2010).pdf

abstract.jpg


Patent Number 244529
Indian Patent Application Number 3467/DELNP/2006
PG Journal Number 50/2010
Publication Date 10-Dec-2010
Grant Date 09-Dec-2010
Date of Filing 16-Jun-2006
Name of Patentee JANSSEN PHARMACEUTICA N.V.
Applicant Address TURNHOUTSEWEG 30, 2340 BEERSE, BELGIUM.
Inventors:
# Inventor's Name Inventor's Address
1 EDDY JEAN EDGARD FREYNE C/O JANSSEN PHARMACEUTICA N.V., OF TURNHOUTSEWEG 30, 2340 BEERSE, BELGIUM.
2 . .
3 TIMOTHY PIETRO SUREN PERERA C/O JANSSEN PHARMACEUTICA N.V., OF TURNHOUTSEWEG 30, 2340 BEERSE, BELGIUM.
4 PETER JACOBUS JOHANNES BUIJNSTERS C/O JANSSEN PHARMACEUTICA N.V., TURNHOUTSEWEG 30, 2340 NEERSE, BELGIUM
5 KRISTOF VAN EMELEN C/O JANSSEN PHARMACEUTICA N.V., OF TURNHOUTSEWEG 30, 2340 BEERSE, BELGIUM.
6 WERNER CONSTANT JOHAN EMBRECHTS C/O JANSSEN PHARMACEUTICA N.V., OF TURNHOUTSEWEG 30, 2340 BEERSE, BELGIUM.
PCT International Classification Number A61K 31/439
PCT International Application Number PCT/EP2004/053497
PCT International Filing date 2004-12-15
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 PCT/EP03/51059 2003-12-18 EUROPEAN UNION